 
  
 
 
 
TAVT -45 (abiraterone acetate)  Granules for Oral Suspension  
 
Clinical Trial Protocol TAVT 45C02 
 
Phase 3  study investigating the efficacy and safety of TAVT -45 (abiraterone acetate)  Granules  
for Oral Suspension (a novel abiraterone acetate formulation)  relative to a reference 
abiraterone acetate formulation  in patients with  
metastatic  Castrate Sensitive Prostate Cancer ( mCSPC)  and metastatic  
Castrate Resistant Prostate Cancer ( mCRPC)  
Document  Type:  Clinical Trial Protocol 
Sponsor Study Number:       TAVT 45C0 2  
IND Number:   139118 
 
EudraCT N umber:   2020- 005611- 46 
 Version N umber:   3.0 
 
Clinical T rial P hase:   3 
 
Date of Protocol :  26 Mar  2021  
 
Sponsor:     Tavanta Therapeutics , Inc.  
101 E. Baltimore Ave, # 602  Media, PA 19063  Tel: +1 833 776 8963
 
  
Property of Tavanta Therapeutics , Inc.  
Confidential   
May not be used, divulged, published, or otherwise disclosed without 
the consent of Tavanta Therapeutics , Inc.   
 
Clinical Trial Protocol Version 3.0 
Confidential  
EudraCT 2020 -005611 -46 Page 2 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
  
 
Study Contacts  
  
Clinical CRO : TMC  Pharma Services Ltd.  
 Lodge Farm Barn 
 Elvetham Park Estate  
 Fleet Road  
 Hartley Wintney, Hants RG27 8AS, UK 
  
Central Laboratory: Covance Central Laboratory  
 7 rue Marcinhes  
 1217 Geneva 
 Meyrin Switzerland  
 Phone 41 58 822 7000 
 Fax: 41 48 822 6999 
  Covance Inc.  
 8211 SciCor Drive 
 Indianapolis, IN 46214 
 Phone: 317 271 1200 
 Fax: 317 273 4030 
 Bioanalytical Laboratory:  Covance Inc.  
 8211 SciCor Drive 
 Indianapolis, IN 46214 
 Phone: 317 271 1200 
 Fax: 317 273 4030             
 Medical Monitor: Dr Peter Hession  
 Email:  TavantaMedical@tmcpharma.com
  
 24/7 support: +44 (0) 125 284 2255 
 Pharmacovigilance: TMC Pharma Ltd.  
 Email: tavanta@tmcpharma.com
  
 EU Fax: +44 (0) 118 900 7822 
 US Fax: +1 617 66 36 222 
 
  
Confidential  
EudraCT 2020 -005611 -46 Page 3 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Signatures for Investigators 
 
CONFIDENTIALITY AND GCP COMPLIANCE STATEMENT  
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, and 
any other drug information provided by the sponsor. I agree to conduct this study in accordance with the requirements of this protocol and also protect the rights, safety, privacy, and well -being of study patient s in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki.  
• International Council for Harmonisation E6 Good Clinical Practice: Consolidated Guideline. 
• All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• Regulatory requirements for reporting serious adverse events defined in Section  7 of this 
protocol. 
Information taken from the study protocol may not be disseminated or discussed with a third 
party without the express consent of the sponsor.  
    
   
Principal Investigator  Name   Signature  
   
  Date  
  
 
  
  
Confidential  
EudraCT 2020 -005611 -46 Page 4 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Signatures for Sponsor   
 
 
 
 
Elizabeth Duus, PhD   
Executive Director , Clinical Development  Signature  
Tavanta Therapeutics , Inc.   
 Date  
 
 
 
Dominic Capone   
Senior Director , Clinical Development  Signature  
Tavanta Therapeutics , Inc.   
 Date  
  
 
Signatures for CRO   
 
Tomasz  Knur owski , MD  
Chief Medical Officer  Signature  
TMC  Pharma .  
 Date  
 
 
 
 
 
 
 
 
Confidential  
EudraCT 2020 -005611 -46 Page 5 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Summary of Revision History  
 
Document Status  Version Date  Summary of Key Changes  
Version 1.0  
(final protocol ) 01 Dec 2020  • Not applicable  
Version 2.0  
(amendment 1)  28 Jan 2021 • Section 5.6.5 (Permitted dose adjustments and 
interruptions  of study treatment) :  added text 
to provide guidance on toxicity management 
during this study related to hepatotoxicity and 
Grade ≥ 3 toxicities , in alignment with Zytiga 
prescribing information  
• Section 5.6.9 (Discontinuation of study 
treatment):   added text to clarify that ALT or 
AST rises above 5x ULN, or total bilirubin rises above 3x ULN, at any time during the 
study will result in permanent discontinuation 
of study medication  
• Section 15 (References):  Added reference #20 
for CTCAE version 5   
Version 3.0  
(amendment 2)  26 Mar  2021  • Study Contacts: Updated email address for 
medical monitor , and added  second Covance 
location for Central Laboratory  
• Synopsis and Section 4.1: Updated  Inclusion 
#10 to exclude herbal supplements only  
• Synopsis and Section 4.2 : Revised definition 
of uncontrolled hypertension in Exclusion #13 
and added new Exclusion #18 concerning post -
trial treatment  
• Sections  5.4, 5.8, and 6:  Added text to clarify 
timing  of randomization, which is to occur 
before Day 1, but after confirming eligibility 
and receiving screening testosterone value  due 
to just- in-time shi pping of study medication  
• Table 1: Revised timing of randomization  
• Section 5.6.7: Added clarifications ar ound 
other concomitant medication that should be 
used with caution during the study  
• Section 5.6.8.2: Added list of notable strong 
CYP3A4 inducers    
• Section 5.10:  Added text to clarify the 
provision of post -trial treatment , including no 
post-trial access to study medication, and the 
definition of “End of Trial ”  
  
Confidential  
EudraCT 2020 -005611 -46 Page 6 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Document Status  Version Date  Summary of Key Changes , continued  
Version 3.0  
(amendment 2)  26 Mar  2021  • Sections 7.1, 7.2.2, 7.2.3, 7.4 and 7.5: 
Added/revised text to better describe timing 
and information needed for reporting AEs, 
SAEs, SUSARs and partner pregnancies  
• Section 9.6: Added t ext to note that additional 
patients may be randomized to ensure that a 
total of 108 patients are treated through Day 9 
for collection of the primary endpoint data  
• Section 9.7.1: Clarified the definition of the 
Per Protocol population  
• Section 10.3: Added text to explicitly state source data should also be readily available 
upon any request from the authorities  
• Section 1 3: Added reference #21 for FDA 
source  of strong CYP3A4 inducers  
 
  
Confidential  
EudraCT 2020 -005611 -46 Page 7 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Contents  
List of figures  ............................................................................................................................ 10 
List of tables  ............................................................................................................................. 10 
List of abbreviati ons ................................................................................................................. 11 
Protocol synopsis  ...................................................................................................................... 14 
1 INTRODUCTION  ................................................................................................. 20 
1.1 Background  ............................................................................................................ 20 
1.2 Investigational medical product  ............................................................................. 21 
1.3 Previous study findings  .......................................................................................... 21 
1.3.1  Nonclinical studies  ................................................................................................. 21 
1.3.2  Clinical studies  ....................................................................................................... 22 
1.3.2.1  Zytiga pharmacokinetics and metabolism ............................................................. 22 
1.3.2.2  Zytiga clinical efficacy and safety  ......................................................................... 22 
1.3.2.3  TAVT -45 clinical experience  ................................................................................ 23 
1.4 Clinical rationale  .................................................................................................... 25 
1.5 Purpose  ................................................................................................................... 25 
2 STUDY OBJECTIVES AND ENDPOINTS  ......................................................... 26 
2.1 Primary objective  ................................................................................................... 26 
2.2 Secondary objective  ............................................................................................... 26 
2.3 Endpoints  ............................................................................................................... 26 
3 INVESTIGATIONAL  PLAN ................................................................................ 27 
3.1 Study design ........................................................................................................... 27 
3.2 Rationale for study design ..................................................................................... 27 
3.3 Rationale for dose/regimen, route of administration and duration of treatment  .... 28 
3.4 Formulation to be used  .......................................................................................... 29 
3.5 Rationale for choice of additional treatment  .......................................................... 30 
3.6 Purpose and timing of interim analyses/design adaptations  .................................. 30 
3.7 Risks and benefits  .................................................................................................. 30 
4 STUDY POPULATION  ........................................................................................ 31 
4.1 Inclusion Cri teria ................................................................................................... 31 
4.2 Exclus ion criteria  ................................................................................................... 33 
5 TREATMENT  ....................................................................................................... 34 
5.1 Study treatment: investigational and control drugs  ............................................... 34 
5.2 Additional treatments  ............................................................................................. 34 
5.3 Treatment arms  ...................................................................................................... 35 
5.4 Treatment assignment and randomization  ............................................................. 35 
5.5 Treatment blinding  ................................................................................................. 35 
5.6 Treati ng the subject  ................................................................................................ 35 
5.6.1  Subject numbering ................................................................................................. 35 
Confidential  
EudraCT 2020 -005611 -46 Page 8 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 5.6.2  Dispensing the investigational  treatment  ............................................................... 35 
5.6.3  Handling of study treatment  ................................................................................... 35 
5.6.4  Instructions for prescribing and taking study treatment ......................................... 36 
5.6.5  Permitted dose adjustments and interruptions of study treatment  ......................... 36 
5.6.6  Rescue medication  ................................................................................................. 37 
5.6.7  Concomitant  medication  ........................................................................................ 37 
5.6.8  Prohibited medication (interaction with other medicinal products and other forms 
of interaction)  ......................................................................................................... 37 
5.6.8.1  Abiraterone acetate contraindications  .................................................................... 38 
5.6.8.2  Effects of other medicinal products on abiraterone acetate  ................................... 38 
5.6.8.3  Effects of abiraterone acetate on other medicinal products  ................................... 38 
5.6.9  Discontinuation of study treatment  ........................................................................ 38 
5.7 Withdrawal of consent  ........................................................................................... 39 
5.8 Lost to  follow -up.................................................................................................... 39 
5.9 Emergency breaking of assigned treatment  code  ................................................... 39 
5.10  Study completion and post -study treatment  ........................................................... 39 
5.11  Early study termination  .......................................................................................... 40 
6 VISIT SCHEDULE AND ASSESSMENTS  ......................................................... 40 
6.1 Information to be collected on screen failures  ....................................................... 43 
6.2 Subject demographics/other baseline  characteristics  ............................................. 43 
6.3 Treatment exposure and  compliance  ..................................................................... 43 
6.4 Contraception  ......................................................................................................... 43 
6.4.1  Exposure to Partners During the Study  .................................................................. 44 
6.4.2  Sperm Donation ..................................................................................................... 44 
6.5 Efficacy assessments  .............................................................................................. 44 
6.5.1  Serum testosterone  ................................................................................................. 44 
6.5.2  Prostate -specific antigen  ........................................................................................ 44 
6.5.3  Abiraterone trough concentrations  ......................................................................... 44 
6.6 Pharmacokinetics  ................................................................................................... 45 
6.7 Safety  ..................................................................................................................... 45 
6.7.1  Clinical laboratory assessments  ............................................................................. 45 
6.7.2  Vital signs  .............................................................................................................. 46 
6.7.3  Electrocardiograms  ................................................................................................ 46 
6.7.4  Physical examination  ............................................................................................. 46 
7 SAFETY MONITORING ...................................................................................... 46 
7.1 Adverse ev ents ....................................................................................................... 46 
7.2 Serious adverse events  ........................................................................................... 48 
7.2.1  Definition of SAE  .................................................................................................. 48 
7.2.2  SAE reporting  ........................................................................................................ 49 
7.2.3  Expedited Reporting .............................................................................................. 50 
Confidential  
EudraCT 2020 -005611 -46 Page 9 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 7.3 Adverse Events of Special Interest  ........................................................................ 50 
7.4 Overdose and dosing errors  ................................................................................... 50 
7.5 Pregnancy reporting  ............................................................................................... 51 
8 DATA REVIEW AND DATABASE MANAGEMENT  ...................................... 51 
8.1 Site monitoring  ...................................................................................................... 51 
8.2 Data collection  ....................................................................................................... 52 
8.3 Database management and quality  control  ............................................................ 52 
8.4 Data Monitoring Committee  .................................................................................. 52 
9 DATA ANALYSIS  ................................................................................................ 53 
9.1 Study design ........................................................................................................... 53 
9.2 Efficacy endpoints  ................................................................................................. 53 
9.3 Safety endpoints  ..................................................................................................... 53 
9.4 Pharmacokinetic endpoints  .................................................................................... 53 
9.5 Other endpoints  ...................................................................................................... 54 
9.6 Sample size ............................................................................................................ 54 
9.7 Data analysis  .......................................................................................................... 54 
9.7.1  General an alyses  .................................................................................................... 54 
9.7.2  Efficacy data analyses  ............................................................................................ 55 
9.7.3  Multiplicity and testing strategy  ............................................................................ 56 
9.7.4  Safety data analyses  ............................................................................................... 56 
9.7.5  Pharmacokinetic data analyses  .............................................................................. 56 
9.7.6  Other analyses  ........................................................................................................ 56 
10 ETHICAL CONSIDERATIONS  ........................................................................... 57 
10.1  Regulatory and ethical  compliance  ........................................................................ 57 
10.2  Informed consent  procedures  ................................................................................. 57 
10.3  Responsibilities of the investigator  ........................................................................ 57 
10.4  Publication of study protocol and results  ............................................................... 57 
11 PROTOCOL ADHERENCE  ................................................................................. 57 
12 PROTOCOL AMENDMENTS  ............................................................................. 58 
13 REFEREN CES ...................................................................................................... 59 
 
 
 
  
Confidential  
EudraCT 2020 -005611 -46 Page 10 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 List of figures  
 
Figure 1                       Study schema  .......................................................................................................... 27 
Figure 2                       Structural formula of the study drug ( abiraterone acetate ) ..................................... 29 
 
 
List of tables  
 
Table 1                      Assessment schedule  ................................................................................................ 41 
 
 
Confidential  
EudraCT 2020 -005611 -46 Page 11 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 List of abbreviations  
ACTH  Adrenocorticotropic hormone  
ADT   Androgen deprivation therapy  
AE   Adverse Event  
AJCC  American Joint Committee on Cancer  
ALP    Alkaline Phosphatase  
ALT    Alanine Aminotransferase  
ANC   Absolute neutrophil count  
ANOVA   Analysis of variance  
AST    Aspartate Aminotransferase  
AUC   Area under the curve  
AUC 0-12  Area under the concentration -time curve from time zero to 12 hours  
AUC 0-24  Area under the concentration -time curve from time zero to 24 hours  
AUC last Area under the concentration -time curve from time zero to the time of last 
sample with a quantifiable concentration  
BID   Twice daily  
CI   Confidence interval  
Cmax   Maximum plasma drug concentration  
Cmin   Minimum plasma drug concentration  
CRF    Case Report Form  
CR-ITT  Intent -to-treat population for the mCRPC patients  
CRO   Contract Research Organization  
CRPC   Castration -resistant prostate cancer  
CSPC   Castration -sensitive prostate cancer  
CT   Computed tomography 
CTCAE   Common Terminology Criteria for Adverse Events  
DHEA   Dehydroepiandrosterone  
dl   Deciliter  
DMC   Data monitoring committee  
ECOG  Eastern Cooperative Oncology Group 
EMA/EMEA  European Medicines Agency  
ET   Early Termination  
FDA   (U.S.) Food and Drug Administration  
GCP    Good Clinical Practice  
GnRH  Gonadotropin- releasing hormone  
Confidential  
EudraCT 2020 -005611 -46 Page 12 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 HbA1c   Hemoglobin A1c  
HBsAg   Hepatitis B surface antigen  
HCV  Hepatitis C virus  
ICF   Informed C onsent Form 
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use  
IEC   Independent Ethics Committee  
IMP   Investigational medicinal products  
IRB   Institutional Review Board  
IRT    Interactive Response Technology 
ITT   Intent -to-treat 
LLOQ   Lower limit of quantification  
LS   Least squares  
mCRPC   Metastatic castration -resistant prostate cancer  
mCSPC   Metastatic castration -sensitive prostate cancer  
MedDRA   Medical dictionary for regulatory activities  
mIU   Milli- International unit  
mm Hg             M illimeter of mercury  
MRI    Magnetic resonance imaging  
NCCN   National Comprehensive Cancer Network  
ng   Nanogram  
PFS   Progression- free survival  
PiB   Powder -in-bottle  
PSA   Prostate -specific antigen  
R-AA  Reference abiraterone acetate ( Zytiga ®) 
Rac   Accumulation index  
RECIST   Response Evaluation Criteria in Solid Tumors  
SAE    Serious Adverse Event  
SE   Standard error  
SmPC   Summary of Product Characteristics  
SUSA R  Suspected unexpected serious adverse reactions  
t½   Effective half -life 
TAVT   Tavanta Therapeutics , Inc.  
TEAE  Treatment -Emergent Adverse Event  
Tmax   Time to maximum plasma concentration  
Confidential  
EudraCT 2020 -005611 -46 Page 13 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 TNM   Tumor, node, metastasis system of staging 
ULN   Upper limit of normal 
WHO   World Health Organization  
Confidential  
EudraCT 2020 -005611 -46 Page 14 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Protocol synopsis  
 
 
Name of Sponsor/Company: Tavanta Therapeutics, Inc. ( Tavanta ) 
Name of Finished Product: TAVT -45 (abiraterone acetate)  Granules  for Oral Suspension,  hereafter 
referred to as TAVT -45 granules  
Name of Active Ingredients: Abiraterone acetate  
Title of Study:  Phase 3  study investigating the efficacy and safety of TAVT -45 (a biraterone 
acetate) Granules for Oral Suspension  (a novel a biraterone acetate formulation)  
relative to a reference abiraterone acetate formulation  in patients with 
metastatic  Castrate Sensitive Prostate Cancer ( mCSPC) and metastatic Castrate 
Resistant Prostate Cancer ( mCRPC)  
Principal 
Investigator:  Multi -center study  
Study Center:  Multi -center study , including but not limited to, sites in US, Europe and other 
regions  
Development Phase:  Phase 3  
Primary Objectives:  
To establish therapeutic equivalence between TAVT -45 granules and Zytiga® tablets in patients with 
metastatic  castrate sensitive prostate cancer ( mCSPC ) and  metastatic castrate resistant prostate cancer  
(mCRPC)   
Secondary Objective:  
To characterize the multiple- dose pharmacokinetic profile of TAVT -45 in a cohort of patients  
Study Design:  
This is a Phase 3 randomized, open- label study to evaluate the pharmacodynamic effect and safety profile 
of TAVT -45 compared to Zytiga (reference a biraterone acetate formulation, hereafter referred to as R -
AA) in patients with mCSPC and  mCRPC. Randomization will be stratified by prostate cancer population 
(CSPC  vs CRPC)  and baseline testosterone (<10 vs ≥ 10 ng/ dL). Patients will be treated for 84 days and 
randomized into one of two groups in a 1:1 ratio: 
• TAVT -45:  Administered twice daily as 1 x sachet containing TAVT -45 (250 mg abiraterone 
acetate)  + Prednisone (5 mg once or twice daily , depending on prostate cancer population)  
• R-AA:  Ad ministered once daily as  (2 x 500 mg Zytiga tablets) + Prednisone ( 5 mg once or 
twice daily , depending on prostate cancer population)  
Methodology:  
At Screening (up to 28 days  prior to first dosing) , all eligible patients  will provide written informed 
consent to participate in the study before any protocol -specified procedures or assessments are initiated .  
Upon meeting all inclusion/exclusion criteria s et forth in the protocol, patients will be randomized in a 
1:1 fashion to receive either TAVT -45 (250 mg abiraterone acetate)  twice daily (approximately every 12 
hours)  without respect to food or R-AA 1000 mg once daily either ≥ 1 hour before or ≥ 2 hours after a 
meal . All patients should also receive prednisone together with a gonadotropin- releasing hormone  
(GnRH) analog concurrently or should have had bilateral orchiectomy . The m CSPC  patients will receive 
prednisone 5 mg orally once daily, while the mCRPC patients will receive prednisone 5 mg orally twice  
daily .  Randomization will be stratified by prostate cancer population (CSPC vs CRPC) and baseline 
testosterone (<10 vs ≥ 10 ng/ dL).  
Patients will return to the clinic in the morning  on Days 9, 10, 28, 56 and 84 for assessments and 
evaluations  of safety and efficacy, including testosterone, PSA, and abiraterone  trough samples .  Patients 
may return to the clinic or may visit a local laboratory for evaluation of liver function tests on Days 42 
and 70 .  Blood samples for testosterone will be taken between the hours of 7 :00-10:00 in the morning . A 
pharmacokinetic sub -study will be conducted in a cohort of up to 8 patients receiving  TAVT -45 at select 
Confidential  
EudraCT 2020 -005611 -46 Page 15 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 site(s) only . Pharmacokinetic profiles  over the dosing interval  will be obtained on Day 1 (first dose) and 
on Day 9 ( steady state).  For all patients, a follow- up phone call will also be made approximately one 
week after the last dose fo r AE assessment s.  
Number of Planned Study Subjects:  
Total patients planned to be enrolled : 108 (n=54 patients per prostate cancer population ), randomized in 
a 1:1 ratio  receiving either TAVT -45(n=27 mCRPC and n= 27 m CSPC patients) or R -AA (n= 27 mCRPC 
and n= 27 m CSPC patients ).  
Inclusion Criteria:  
1. Written informed consent obtained prior to any study-related procedure being performed  
2. Male patients at least 18 years of age or older at time of consent  
3. Pathologically confirmed adenocarcinoma of the prostate  
4. Ongoing therapy with a gonadotropin releasing hormone (GnRH) agonist or antagonist (unless 
patient has already had a bilateral orch iectomy ) AND serum testosterone  level <50 ng/dL at 
screening  
5. Have either metastatic CS PC or metastatic CRPC, as defined below:  
• CSPC :   Using the American Joint Committee on Cancer (AJCC) tumor, node, metastasis 
(TNM) system, patients must have Stage T any Nany M+ (distant metastases) disease AND two 
of the following:  
• Gleason score of 8 or greater  
• Three or more bone scan lesions 
• Measurable visceral metastases  
• CRPC:  Patients must have metastatic* disease, and mu st also have disease progression 
according to the recommendations of the Prostate Cancer Working Group 3 by having at 
least one of the following criteria:  
• Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement 
of at least 1 ng/mL  
• Imaging progression (CT/MRI) by RECIST 1.1 criteria or PET/CT*  
• Nuclear scan progression by 2 or more new bone lesion s.  
* Note:  Metastatic disease should be documented by MRI/CT, PET/CT (including, but not 
limited to, standard of care imaging using 18F-fluciclovine, 11C-choline, or PSMA  where 
approved) or bone scan. Imaging obtained within 90 days prior to the start of study 
drug/reference product will be accepted . 
6. The following prior treatment and /or surgery for prostate cancer are allowed:  
• CSPC:     
• Up to 90 days  of androgen deprivation therapy (ADT) with gonadotropin- releasing 
hormone ( GnRH) agonists /antagonists  or orchiectomy with or without concurrent 
anti-androgens prior to patients’ randomization is permitted  
• Patients may have one course of palliative radiation or surgical therapy to treat 
symptoms resulting from metastatic disease (e.g., impending cord compression or 
obstructive symptoms) if administered prior to randomization  
• Radiation or surgical therapy that was not  initiated 4 weeks after the start of ADT  or 
orchiectomy  
• CRPC: 
• Previous chemotherapy with docetaxel for metastatic disease with treatment 
completed at least 1 year prior to Screening  
7. Discontinuation of flutamide or nilutamide , and other anti -androgens prior to the start of study 
medication; discontinuation of bicalutamide prior to start of study medication.  
8. Discontinuation of strong CYP3A4 inducers at least 4 weeks prior to start of study medication . 
Confidential  
EudraCT 2020 -005611 -46 Page 16 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 9. Discontinuation of radiotherapy prior to start of study medication  
10. Discontinuation of herbal supplements at least 4 weeks prior to the first dose of study medication 
and for the duration of the trial.   
11. Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 at s creening  
12. Normal organ function with acceptable initial laboratory values within the screening period :  
ANC  ≥ 1,500/µl 
Albumin 
Hemoglobin  > 3.0g/dL  
≥ 9g/dL 
Platelet count ≥ 100,000/µl 
Serum Creatinine  ≤ 3.0 x the institutional upper limit of normal (ULN)  
Potassium  > 3.5 mmol/L (within institutional normal range)  
Bilirubin  ≤ 1.5 ULN (unless documented Gilbert's disease)  
SGOT (AST)  ≤ 2.5 x ULN 
SGPT (ALT)  ≤ 2.5 x ULN 
13. Life expectancy of at least 6 months at screening  
14. Patients engaged in sex with women of child- bearing potential agree to use a condom plus another 
effective contraception method .  Patients agree to use a condom when engaged in any sexual activity, 
includi ng sex with a pregnant woman. These restrictions will apply from the time informed consent 
is provided until 3 weeks after the last dose of study medication is taken. 
15.  Patient is  willing and able to comply with all protocol requirements assessments  
Exclusion Criteria:  
1. For m CSPC patients:  
• Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer  not 
specified as allowable treatment in Inclusion C riteri on 6. For example, p rior therapy with 
apalutamide  or enzalutamide is prohibited  as well as therapy with an investigational agent 
as described in Exclusion Criterion 16 . 
2. For m CRPC patients:  
• Prior treatment with abiraterone  or enz alutamid e is prohibited  
• Previous chemotherapy is prohibited with exception of docetaxel treatment as specified in 
Inclusion Criterion 6. 
3. Initiation of bisphosphonate or denosumab therapy within 4 weeks prior to the start of study 
drug/reference product. Patients who are on a stable dose of these medications for at least 4 week s 
at the time of starting study drug/reference product will be  eligible.  
4. Therapy with estrogen within 4 weeks prior to the start of study drug 
5. Use of systemic glucocorticoids equivalent to >10 mg prednisone daily. Patients who have 
discontinued or reduced dosing to the equivalent of ≤ 10 mg prednisone daily within 14 days prior 
to the start of study drug are eligible  
6. Known , symptomatic  metastases  to the brain or central nervous system involvement  (patients with 
asymptomatic and neurologically stable disease for the past 4 weeks will be permitted)  
7. History of adrenal gland dysfunction  defined as requiring treatment for adrenal insufficiency  
8. History  of other malignancy within the previous 2 years (no longer being actively treated), with the 
exceptions of basal cell carcinoma, non -muscle invasive bladder cancer that has been treated and is 
under surveillance, or other in-situ cancers with a low likelihood of recurrence  
9. Major surgery within 4 weeks  prior to the start of study drug  
10. Known gastrointestinal disease or condition that could impair absorption inclu sive of gastrocolic 
fistula, gastroenterostomy, biliary obstruction, cirrhosis, chronic pancreatitis or pancreatic cancer, 
cystic fibrosis, amyloidosis, celiac disease, Crohn’s disease, radiation enteritis, intestinal resection, 
and history of bariatric surgery  
Confidential  
EudraCT 2020 -005611 -46 Page 17 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 11. Known history of human immunodeficiency virus or seropositive test for hepatitis C virus (HCV) or 
hepatitis B surface antigen  (HBsAg)  (note: HCV patients with undetectable viral load will be 
eligible)  
12. Poorly controlled diabetes , defined as HbA1c  > 8% within the past 12 months   
13. Uncontrolled hypertension at screening  
14. History of New York Heart Association class III or IV heart failure  
15. Serious concurrent illness, including psychiatric illness, that could interfere with study participation  
16. Receipt of another inves tigational agent within 4 weeks of treatment start  or within  5 x the treatment 
half-life, whichever is longer . 
17. Known hypersensitivity or allergy  to abiraterone acetate, prednisone or any excipients in the study 
drugs  
18. In the opinion of the investigator, participation in the trial would prevent the patient from receiving 
local standard -of-care treatment for metastatic prostate cancer , if clinically indicated, after 
completion of the trial  
19. Other condition which, in the opinion of the Investigator, would preclude participation in this trial.  
Test Product, Dose and Mode of Administration  
Test product:  TAVT -45 (250 mg abiraterone acetate)  
Mode of 
administration: Oral  
Strength:  250 mg  
Dose:  Administered twice daily as 1 x sachet TAVT -45 (250 mg abiraterone 
acetate) reconstituted in either water or juice, as specified in the medication 
preparation guide  
Reference Product, Dose and Mode of Administration  
Reference product:  Reference abiraterone acetate (R -AA; Zytiga tablets)  
Mode of administration: Oral 
Strength:  500 mg Zytiga  tablets  
Dose:  Administered once daily as 2 x 500 mg Zytiga tablets , swallowed whole with 
water  
Additional  Product, Dose and Mode of Administration  
Additional  product:  Prednisone  
Mode of 
administration: Oral 
Strength:  5 mg tablets  
Dose:  mCRPC Patients : 5 mg twice daily  
mCSPC Patients:  5 mg once daily  
Duration of Treatment:  
For an individual patient , the duration of the clinical study will be up to approximately 17  weeks 
(including a Screening Phase up to 28 days, a n 84-day treatment period, and a 1 -week follow up period).   
Efficacy  Assessments:  
Efficacy assessments will include:  
• Serum testosterone  
• Prostate specific antigen (PSA)  
• Trough concentrations of abiraterone  
Confidential  
EudraCT 2020 -005611 -46 Page 18 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Pharmacokinetic Assessments:  
In a cohort of up to 8 patients randomized to TAVT -45, blood samples (approximately 4 mL each) for 
PK analysis will be collected at the following times on Day 1 and Day 9: pre -dose (time 0) and  0.25, 
0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, and 12 hours post -dose and before the scheduled evening dose .   
Safety A ssessments:  
Safety assessments will include : 
• Vital sign s 
• Physical examinations  
• Adverse events (AEs)  
• Clinical laboratory assessments  
Criteria for Evaluation:  
Efficacy:  
The primary efficacy endpoint is the comparison of the average of serum testosterone levels on days 9 
and 10 between groups ( TAVT -45 vs R- AA). 
The key secondary efficacy endpoint  is the PSA -50 response, defined as a decrease of ≥  50% in PSA 
levels from baseline  at any time over the 84-day post- treatment period . 
Other secondary efficacy endpoints are as follows:  
• Serum testosterone levels at Day s 28, 56 and 84 
• PSA-50 response at Days 28, 56 and 84 
• PSA levels at Day s 28, 56 and 84 
• Trough concentrations of abiraterone  at Day s 9, 28, 56 and 84 
 
Safety:  Safety endpoints include incidence of treatment emergent adverse events (TEAE), and clinically 
relevant changes in vital signs and laboratory assessments.  
 
Pharmacokinetics :  For a cohort of up to 8 patients randomized to TAVT -45 and participating in the 
serial PK sampling on Day 1 and Day 9, the following PK parameters will be determined:  
• Area under the concentration- time curve from time zero to 12 hours post dose ( AUC 0-12)  
• Maximum measured plasma concentration (C max)  
• Minimum measured plasma concentration (C min)  
• Time to maximum measured concentration (t max)  
• Accumulation ratio (Rac) 
• Effective half -life (t ½) 
Statistical Methods: The effects of TAVT -45 250 mg BID on serum testosterone will be  compared to 
R-AA ( 1000 mg QD) based on the equivalence approach of 80% to 125% confidence interval (CI) of the 
test-to-reference geometric mean ratio. Under the assumptions of a coefficient of variation of 25%, a 
lower and upper limit of 80% to 125%, and an expected test -to-reference ratio of 1. 05, 108 patients  in 
total ( 54 patients in TAVT -45 and 54 patients in R -AA) will provide o ver 80% power (two one -sided t -
tests at 0.05 level) to conclude therapeutic equivalence of TAVT -45 to R- AA. 
The primary endpoint, the average serum testosterone levels on days 9 and 10, will be analyzed by an 
analysis of variance  (ANOVA) model with treatment as a factor. The test -to-reference geometric mean 
ratio effect and its 90% confidence interval (CI) of TAVT -45 to R-AA will be compared to 80% to 125%  
limit [1,2] . The primary analysis will be performed on the mCRPC intent- to-treat (CR-ITT)  population 
and repeated on the ITT and per-protocol populations . Primary analysis will also be repeated on CSPC 
patients. Differen t missing data imputation approaches will be used as sensitivity analyses based on the 
intent- to-treat population.  If the equ ivalence of the average of serum testosterone levels on days 9 and 
10 is achieved, th en the key secondary endpoint  (PSA-50 response) will be tested at 0.05 alpha level.  
Confidential  
EudraCT 2020 -005611 -46 Page 19 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Safety will be  assessed in all patients who received at least one dose of study drug. Treatment -emergent 
AEs, along with the number and percentage of patients with abnormal or potentially clinically significant 
clinical laboratory values and vital sign measurements , will be summarized by treatment. Hypothesis 
testing, unless otherwise indica ted, will be  performed at the 5% significance level.  
Confidential  
EudraCT 2020 -005611 -46 Page 20 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
  
1 INTRODUCTION 
1.1 Background  
Abiraterone acetate is rapidly converted in vivo to abiraterone, a selective, irreversible inhibitor 
of cytochrome P450 17α (17α-hydroxylase/C17- 20 lyase; CYP17), an enzyme that is key in the 
production of androgens in all sites, including the testes and adrenal glands. CYP17 catalyses the conversion of pregnenolone and progesterone into testosterone precursors, dehydroepiandrosterone (DHEA)  and androstenedione  [3,4]. Inhibition of this  biochemical 
process results in dec reased proliferation of androgen sensitive castration -resistant prostate cancer 
(CRPC)  cell lines and slower disease progression in patients. 
Abiraterone acetate is indicated for the treatment of metastatic castration -resistant prostate cancer 
(mCRPC)  and metastatic high -risk castration -sensitive prostate cancer (CSPC) , in combination 
with prednisone  in the US and in combination with either prednisone or prednisolone  in Europe . 
Abiraterone acetate is currently marketed under the trade name Zytiga as film -coated tablets 
containing 500 mg a biraterone acetate and as uncoated tablets containing 250 mg. The 
recommended dose for Zytiga is 1000 mg orally once daily, together  with 
prednisone /prednisolone  (5 mg orally twice daily for m CRPC patients; and 5 mg orally once daily  
for high- risk CSPC patients). Patients receiving Zytiga  should also receive a gonadotropin-
releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy  [3,4]. 
Abiraterone acetate has been  shown to be safe and effective in both the  CRPC and high- risk CSPC 
populations  with dista nt metastases (M1, according to the American Joint Committee on Cancer 
[AJCC] tumor, node, metastasis [TMN] system ). Of note, a biraterone acetate is also recommended 
as Category 1 evidence by the National Comprehensive Cancer Network ( NCCN ) as first -line 
treatments for both populations ( i.e., nodal  metastas es [N+M0]). 
Administration of Zytiga with food, compared with administration in a fasted state, results in up to a 10- fold (AUC) and up to a 17- fold (C
max) increase in mean systemic exposure of abiraterone, 
depending on the fat content of the meal. Given the normal variation in the content and composition of meals, taking Zytiga with meals has the potential to result in highly variable exposures. Therefore, Zytiga must not be taken with food. It should be taken at least two hours after eating and no food should be eaten for at  least one hour after taking Zytiga. The 10- fold food 
effect observed also shows that the oral bioavailability of abiraterone is below 10% when Zytiga is administered in the fasted state.  Inter -subject variability has been shown to be approximately 
79% for C
max and 64% for AUC 0-24 after multiple day dosing. 
The objective of the TAVT -45 development program was to develop an abiraterone acetate 
formulation with improved oral bioavailability through enhanced solubility in the fasted state , 
thereby decreasing the food effect observed after the oral administration of Zytiga. This would eliminate the requirement of taking the drug on an empty stomach, would allow significant 
reduction of the dose , and would reduce the high variability of exposure . Additionally, and 
importantly, the oral suspension formulation of 
TAVT -45 addresses the unmet medical need of 
prostate cancer patients who have difficulty swallowing the currently approved 500 mg filmcoa ted 
tablet and the 250 mg uncoated tablet formulations  of Zytiga. Both presentations require patients 
to swallow multiple, large tablets daily. T his is of particular importance since dysphagia, defined 
as difficulty or discomfort in swallowing, has been re ported to affect ~20% to 40% of cancer 
patients and can impact compliance to prescribed medications due to difficulty swallowing pills  
[5,6,7] . As an oral suspension, TAVT -45 provides an alternative formulation and choice for cancer 
patient s with and without dysphagia and reduces the pill burden in these patients. 
Confidential  
EudraCT 2020 -005611 -46 Page 21 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 1.2 Investigational medical product  
The following investigational medicinal products (IMPs) will be used in this clinical study:  
   
• TAVT -45:  Administered twice daily as 1 x sachet containing TAVT -45 (250 mg 
abiraterone acetate) .  Each sachet is reconstituted in water  or specified fruit juice . 
• Reference abiraterone acetate (R-AA):  Administered once daily as (2 x 500 mg Zytiga 
tablets).  Tablets  are administered with water.  
1.3 Previous s tudy findings  
Three novel  formulations of  abiraterone acetate have been used to support the clinical 
development .  Initial formulations were identified as DRGT -45, while the final formulation to be 
evaluated in this study is identified as TAVT -45.  
Initially , a powder -in-bottle ( PiB) formulation with 50 mg abiraterone acetate per bottle  strength 
was developed and tested in both non- clinical  studies and a Phase 1 clinical  trial. Since the 
production of the PiB formulation at industrial scale is not viable and PiBs are generally not 
preferred as final marketed dosage forms, DRGT -45 tablet s for oral suspension (with 62.5 mg 
strength)  were developed .  The DRGT -45 tablets for oral suspension were used in one Phase 1 
clinical trial and whilst the clinical data was acceptable, the tablets  were found to have a high level 
of friability  which could impact on the physical integrity of the tablets when manufactured at large 
scale or d istributed for use outside of a controlled clinical setting . To address the tablet friability 
issue, the tablet manufacturing process was modified to deliver a granule form (TAVT -45) which 
had an  identical formulation  composition but was a granule  in place of a tablet. The granules  are 
packaged in a sachet  as the primary packaging which is composed of the same material used in 
primary packaging of the tablets. Characterization studies were performed to confirm that the reconstitution properties (ti me and reconstitution method) of the granules  were comparable to that 
of the tablets  and also that the properties of the reconstituted granules  in water and fruit juice were 
equivalent in terms of homogeneity and stability compared to that obtained when re constituting 
the tablets in water .  The granule  formulation of 
TAVT -45 will be used in this study.  
1.3.1  Nonclinical s tudies  
The non- clinical aspects of abiraterone acetate are well documented [ 3,4]. Bridging studies , 
however, using DRGT -45 PiB, DRGT -45 tablet for oral suspension, and TAVT -45 granules for 
oral suspension have been undertaken.  Comparisons of DRGT -45 PiB and DRGT -45 table t for 
oral suspension have been assessed in vitro and in vivo and TAVT -45 granules  have been assessed 
in vitro . The aim of the non- clinical investigation was to assess the pharmacokinetic properties of 
the novel formulations using in vitro dissolution and permeability measurements along with in vivo pharmacokinetic investigations in beagle dogs  for the DRGT -45 tablet for oral suspension.   
Since the formulation  composition of the DRGT -45 tablet and TAVT -45 granules  are the same 
and the in vitro dissolution and properties of the reconstituted products  are comparable, the in 
vivo pharmacokinetic investigation in vivo has not been repeated for the TAVT -45 granules.  
Full details of nonclinical assessments  may be foun d in the TAVT -45 Investigator Broc hure 
[8]. 
Confidential  
EudraCT 2020 -005611 -46 Page 22 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 1.3.2  Clinical studies  
Abiraterone acetate has been investigated extensively as Zytiga  in healthy volunteers and patients  
[3, 4]; further clinical study results are available in the Investigator’s  Brochure [ 8], and are 
discussed below.  
There has been one clinical study conducted with the DRGT -45 PiB formulation , and one clinical 
study with this DRGT -45 tablet for oral suspension formulation, which are both briefly discussed 
below  in Section 1.3.2.3.  
1.3.2.1  Zytiga p harmacokinetics and metabol ism  
Following administration of Zytiga, the PK of abiraterone and abiraterone acetate have been 
studied in healthy subjects, patients with metastatic advanced prostate cancer and subjects without cancer with hepatic or renal impairment. Abiraterone acetate is rapidly converted in vivo to abiraterone, an androgen biosynthesis inhibitor.  
Following oral administration of abiraterone acetate in the fasting state, the time to reach 
maximum plasma abiraterone concentration is approximately 2 h ours. No major deviatio n from 
dose proportionality was observed in the dose range of 250 to 1000 mg. Steady state is achieved 
within eight days following once -daily dosing of 1000 mg, with approximately 2- fold higher 
exposure at steady state (steady state AUC) compared to when t he same dose is administered as a 
single dose. Inter -subject variability has been shown to be approximately 79% for C
max and 64% 
for AUC 0-24 after multiple day dosing.  
Following oral administration of 14C-abiraterone acetate as capsules, abiraterone acetate is 
hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver. The majority of circulating radioactivity (approximately 92%) 
is found in the form of metabolites of abiraterone. Approximately 88% of the radioactive dose is 
recovered in faeces and approximately 5% in urine . 
Administration of abiraterone acetate with food, compared with administration in a fasted state, results in up to a 10-fold (AUC) and up to a 17- fold (C
max) increase in mean systemic exposure of 
abiraterone, depending on the fat content of the meal. Given the normal variation in the content and composition of meals, taking Zytiga with meals has the potential to resul t in highly variable 
exposures. The mean half -life of abiraterone in plasma is approximately 15 h based on data from 
healthy subjects.  
The plasma protein binding of 
14C-abiraterone in human plasma is 99.8%. The apparent volume 
of distribution is approximat ely 5630 L suggesting that abiraterone extensively distributes to 
peripheral tissues [ 4]. 
1.3.2.2  Zytiga  clinical efficacy and safety  
Zytiga  decreases serum testosterone and other androgens to levels lower than those achieved by 
the use of gonadotropin- releasing hormone ( GnRH) analogues alone or by orchiectomy. This 
results from the selective inhibition of the CYP17 enzyme required for androgen biosynthesis . 
The key studies wi th Zytiga include two randomized placebo- controlled, multicenter Phase 3  trials 
in patients with metastatic CRPC (COU -AA-301 and COU -AA-302) and one randomized 
placebo -controlled, multicenter Phase 3  trial (LATITUDE) in patients who had metastatic high -
risk CSPC [ 9,10,11]. In these trials, Z ytiga  was administered orally at a dose of 1,000 mg daily in 
combination with prednisone 5 mg (twice daily for m CRPC patients and once daily for high- risk 
CSPC) , and added to standard androgen deprivation therapy (ADT) , consisting of either a 
gonadotropin- releasing hormone (GnRH) analog or prior orchiectomy.  In the m CRPC patients , 
Confidential  
EudraCT 2020 -005611 -46 Page 23 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 overall survival was prolonged in the Zytiga –prednisone group compared to th e placebo –
prednisone group in both patients who previously received chemotherapy  [9] and those who were 
chemotherapy naïve [ 10]. Similarly, in patients with metastatic high -risk C SPC, addition of 
Zytiga -prednisone to ADT significantly increased overall survival and radiographic progression-
free survival in men with newly diagnosed, metastatic, CSPC [ 11]. These studies also 
demonstrated that Zytiga was well tolerated. Most t oxic effects were predominantly grade 1 or 2, 
with a low  rate of drug discontinuation or dose reduction and were largely mechanism -based and 
secondary to mineralocorticoid excess resulting from blockade of CYP17. The common adverse 
events (≥1%) resulting in di scontinuation of Zytiga -prednisone were hepatotoxicity and cardiac 
disorder .  
The current NCCN guidelines for treatment of prostate cancer also recommends Zytiga  usage in 
high- risk CSPC patients  with nodal metastases ( N+ M0). This is based, in part, on the findings 
from the STAMPEDE trial, which  demonstrated that adding abiraterone leads to an increased life 
expectancy and improvement in disease control in newly diagnosed metastatic or node -positive 
disease [ 12]. 
An additional observational study show ed that abiraterone trough concentration correlates with 
PSA response and progression- free survival ( PFS). Moreover, a cut -off value for  plasmatic 
concentration (8.4 ng/mL) was determined for PSA response  [13]. These data show that t here is a 
relationship between steady state abiraterone trough concentrations , primary treatment resistance, 
and efficacy response ( PSA and P FS). Of note, since Zytiga exhibits highly variable PK , low 
plasma abiraterone concentrations are not infrequent. This highlights a major limitation for Zytiga.  
1.3.2.3  TAVT -45 clinical e xperience  
Tavanta initially  performed one clinical study in healthy male vol unteers  using an initial 
DRGT -45 PiB formulation. Study DRGT 45C01 was a single center, open- label, non- randomized, 
single dose, fixed sequence, 2 -way crossover study in 11 healthy male subjects , whereby 
DRGT -45 PiB was dosed at 100 mg and 200 mg doses in the fasted state and at 200 mg dose in 
the fed state, with a minimum washout period between doses of 7 days.  Following the administration of DRGT -45 PiB, the mean abiraterone plasma concentrations increased r apidly to 
peak and declined in a biphasic manner. Mean T
max occurred within 1 hour regardless of the dose 
or prandial status. For the 200 mg dose, abiraterone was detectable in plasma for up to 72 hours (> 0.2 ng/ml), while for the 100 mg dose it was detec table for up to 48 hours. The calculated PK  
parameters were compared to literature data available across multiple studies for 1,000 mg Zytiga [14]. Following the admi nistration of 100 mg PiB in the fasted state, C
max and AUC were 88% 
and 33% of that following the administration of 1,000 mg Zytiga, respectively. At the 200 mg dose in the fasted state, C
max exceeded that of 1,000 mg Zytiga by over 2 -fold, while AUC was 
81% of the 1,000 mg Zytiga. Increasing the dose from 100 mg to 200 mg resulted in a 2.5- fold 
increase in AUC. Inter -subject variability (expressed as CV%) was also reduced from 59% 
(Zytiga) to 38% (100 mg dose) and 29% (200 mg dose). Food slightly delayed a bsorption and 
reduced the AUC by 26%. The terminal elimination half -life was similar to that reported for 
Zytiga  [3, 14]. There were no serious adverse events (SAEs) or deaths reported during this study. 
All AEs were assessed as mild and unrelated to study drug. The most common TEAEs reported by at least 2 subj ects were musculoskeletal pain (back/joints) and headache. Other TEAEs 
reported were nasopharyngitis, blood creatine phosphokinase and transaminase increase. There were no other clinically significant changes reported in hematological, clinical chemistry o r 
urinalysis laboratory values, vital signs measurements, physical examinations, or 12- lead ECGs.  
Tavanta then performed one clinical study in healthy male volunteers  using the DRGT -45 tablet 
for oral suspension formulation. Study DRGT 45C0 3 was a single ce nter, r andomized crossover 
Confidential  
EudraCT 2020 -005611 -46 Page 24 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 trial to evaluate the PK and safety of single doses of DRGT -45 tablets for oral suspension (Part 1; 
doses of 62.5 to 250 mg  in 12 healthy adult males) and to compare the oral bioavailability of 
DRGT -45 (250 mg)  and R -AA (1000 mg)  under f ed and modified fasting c onditions (Part 2; in 
20 healthy adult males).  
Part 1:   Following single oral administration of DRGT -45 at doses of 62.5, 125, 187.5 and 250 mg, 
abiraterone was rapidly absorbed with median T max occurrin g between 0.50 h and 1.50 h post -
dose across the 62.5 to 250 mg dose range. Exposure to abiraterone increased in a dose supra -
proportional manner. A doubling of the dose of DRGT -45 would result in a 3.11- fold, 3.14 -fold 
and 3.05- fold average increase in ex posure as measured by C max, AUC 0-last, and AUC 0-∞, 
respectively. The geometric mean plasma half -life of abiraterone was 10.379 h for the 62.5 mg 
dose level and increased to range from 14.045 to 15.038 h at the 125, 187.5 and 250 mg dose 
levels which was si milar to those observed previously, and likely the result of better definition of 
the terminal portion of the curve at higher doses (median T last increased from 24 h at the 62.5 mg 
dose level to 71 h at the 187.5 and 250 mg dose levels).  
Single oral doses  of DRGT -45 up to 250 mg in the fasted state were well tolerated and there were 
no deaths during the study. Six (50.0%) subjects reported a total of 14 AEs after dosing with DRGT -45 in Part 1. The overall incidence of AEs was low across all dose levels and  the majority 
of AEs were mild in severity and unrelated to DRGT -45. Two subjects were withdrawn due to 
AEs during Part 1 of the study. One subject had an unrelated SAE that that was of moderate severity and led to withdrawal from the study (buttock abscess). One subject was withdrawn due to maculopapular rash that was mild in severity and considered possibly related to DRGT -45. 
There were no significant clinical laboratory, vital signs or ECG results. 
 
Part 2:  Administration of DRGT -45 at 250 mg with a high- fat breakfast showed a statistically 
significant reduction of 59.61%, 24.88% and 24.74% in C max, AUC 0-last and AUC 0-∞ of 
abiraterone, respectively, compared to the fasted state. Median T max was unchanged in t he fed 
state compared with the fasted state at 0.500  hours and this was confirmed by the statistical 
analysis. The parameters associated with exposure of abiraterone in the fasted treatment group in Part 2 were consistent with same treatment in Part 1. Elimination of abiraterone was unchanged in the fed state, with geometric mean terminal half -life of 14.624 hours, and was also similar to 
that seen in the fasted state in Part  1.  
Administration of R -AA at 1000 mg 2 hours after a high- fat breakfast (modified  fasting 
conditions) showed a delay of 1.5 hours in median T max to 3.000 hours compared with the same 
dose in the fasted state. This delay is likely due to delayed gastric emptying in the fed state, and median T
max in both fasted and modified fasted states  was later than that of DRGT -45. The C max, 
AUC 0-last and AUC 0-∞ values were 782%, 650% and 642% higher in the modified fasted state than 
the fasted state. Elimination of abiraterone was similar in the fed state to the fasted state, with geometric mean terminal half -life of 13.829 hours. 
Following administration of 250 mg DRGT -45 in the fed state, exposure was approximately 
equivalent to or moderately higher than that of 1000 mg R -AA in the fasted state, with C
max 
bioavailability of 121.11% and AUC 0-last and AUC 0-∞ bioavailability of 91.24% and 90.46%, 
respectively. Conversely, when compared to that of 1000 mg R -AA dosed in the modified fasted 
state, representing an upper safety limit for the exposure range, exposure levels were notably less than the reference regimen (relative bioavailabilities of 15.47%, 14.00% and 14.10% for C
max, 
AUC 0-last and AUC 0-∞, respectively) indicating that fed dosing did not represent any exposure 
driven safety concerns.  
Although administration of DRGT -45 at 250 mg with a high- fat breakfast showed a statistically 
significant reduction in abiraterone exposure levels compared to fasted dosing, similar 
Confidential  
EudraCT 2020 -005611 -46 Page 25 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 conclusions can be drawn for 250 mg DRGT -45 dosed in the fasted state when comparing to the 
reference Zytiga regimens. Comparisons to 1000 mg R -AA in the fasted state indicated increased 
abiraterone exposure for the DRGT -45 regimen with relative bioavailabilities of 299.83%, 
121.46% and 120.19% for C max, AUC 0-last and AUC 0-∞, respectively. In spite of the negative food 
effect, abiratero ne exposure levels following fasted DRGT -45 dosing (relative bioavailabilities of 
59.61%, 24.88% and 24.74% for C max, AUC 0-last and AUC 0-∞, respectively, when compared with 
fed dosing) were also notably less than that observed for R -AA dosed in the modifie d fasted state. 
The notable gap that exists between DRGT exposure, regardless of prandial state dosed, and the 
upper end of Zytiga exposure, highlights there exists a wide safety related exposure margin for future increases in DRGT -45 dose or modification in dose regimens (e.g., BID dosing).  
Additionally, DRGT -45 dosing was associated with lower  variability than for R -AA, regardless 
of prandial status  (CV% for C
max was 48.0- 60.4% vs 58.6- 72.3% , respectively ; and CV% for 
AUC 0-∞ was 44.0- 45.1% vs 5 5-56.3%).  
Single oral doses of 250 mg DRGT -45 and 1000 mg R -AA administered in the fed and fasted 
state were well tolerated in healthy male subjects and the incidence and nature of AEs was similar after dosing with DRGT -45 and R -AA. The incidence of AEs was low across all dosing regimens 
and the majority of AEs were both mild in severity and unrelated to IMP. Twelve (60.0%) subjects reported 22 AEs after dosing with DRGT -45 and R -AA. There were no deaths, severe AEs, SAEs 
or AEs leading to withdrawal during Part 2 of the study and there were no significant clinical laboratory, vital signs or ECG results. 
1.4 Clinical rationale  
The low bioavailability, significant food effect and the highly variable nature of abiraterone PK  
after dosing with Zytiga  results in known efficacy and potential safety issues. As noted above, i t 
has been shown that patients who exhibited primary resistance to 1,000 mg Zytiga  had lower 
plasma  abiraterone concentrations when compared to responders  [13]. Therefore, TAVT -45 is 
being developed to have an abiraterone acetate formulation with improved oral bioavailability , 
and thus the highly variable nature of abirat erone exposure seen after Zytiga dosing is expected 
to be reduced  with TAVT -45 dosing. This may result in a greater proportion of patients having 
abiraterone trough concentrations exceeding the 8.4 ng/mL threshold after TAVT -45 treatment 
compared to Zytiga . Moreover, through enhanced solubility in the fasted state, it is expected that 
TAVT -45 would decreas e the positive food effect observed after the oral administration of Zytiga , 
eliminating the requirement of taking the drug on an empty stomach. The improved bioavailability 
of TAVT -45 would also allow significant reduction of the dose  compared to Zytiga . Finally, 
TAVT -45 would be the first and only anti -androgen therapy that does not increas e patient pill-
burden in that it is dosed as a suspension in water  or fruit juice . The oral suspension formulation 
of TAVT -45 also addresses the unmet medical need of prostate cancer patients who have difficulty 
swallowing the currently approved 500 mg fil m-coated tablet and the 250 mg uncoated tablet 
formulations of Zytiga. This is of particular importance since dysphagia, defined as difficulty or 
discomfort in swallowing, has been reported to affect ~20% to 40% of cancer patients and can impact compliance  to prescribed medications due to difficulty swallowing pills  [5,6,7] .  
1.5 Purpose  
This study aims to establish therapeutic equivalence of clinical efficacy and safety betw een 
TAVT -45 and Zytiga in patients with m CSPC  (distant metastases) and m CRPC.   
Confidential  
EudraCT 2020 -005611 -46 Page 26 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
  
2 STUDY OBJECTIVES AND ENDPOINTS  
2.1 Primary objective 
The primary objective of this study is t o establish therapeutic equivalence between TAVT -45 
granules and Zytiga  tablets , hereafter referred to as reference abiraterone acetate (R-AA), in 
patients with m CSPC and m CRPC. 
2.2 Secondary objective 
The secondary objective of this study is t o characterize the multiple -dose pharmacokinetic profile 
of TAVT -45 in a cohort of patients. 
2.3 Endpoints 
Efficacy:  
The primary efficacy endpoint is the comparison of the average of serum testosterone levels on 
days 9 and 10 between groups ( TAVT -45 vs R- AA).  
The key secondary efficacy endpoint  is the PSA -50 response, defined as a decrease of ≥  50% in 
PSA levels from baseline  at any time over the 84-day post- treatment period . 
Other secondary efficacy endpoints are as follows: 
• Serum testosterone levels at Day s 28, 56 and 84 
• PSA-50 response at Days 28, 56 and 84 
• PSA levels at Day s 28, 56 and 84 
• Trough concentrations of abiraterone at Days 9, 28, 56 and 84 
Safety:   
Safety endpoints include incidence of treatment emergent adverse events (TEAE), and clinically relevant changes in vital signs and laboratory assessments. 
For more details on study endpoints, see Section 9. 
Pharmacokinetics:  
For a cohort of up to 8 patients randomized to TAVT -45 and participating in the  serial PK 
sampling on Day 1 and Day 9, the following PK parameters will be determined: 
• Area under the concentration -time curve from time zero to 12 hours post dose (AUC 0-12)  
• Maximum measured plasma concentration (C max)  
• Minimum measured plasma concentrat ion (C min)  
• Time to maximum measured concentration (t max)  
• Accumulation ratio (Rac)  
• Effective half -life (t½)  
 
Confidential  
EudraCT 2020 -005611 -46 Page 27 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 3 INVESTIGATIONAL  PLAN  
3.1 Study design  
This is a Phase 3 randomized, open- label study to evaluate the pharmacodynamic effect of TAVT -
45 compared to Zytiga (reference abiraterone acetate formulation, hereafter referred to as R -AA) 
in patients with m CSPC (distant metastases) and mCRPC. Randomizat ion will be stratified by 
prostate cancer population (CSPC vs CRPC) and baseline testosterone (<  10 vs ≥ 10 ng/ dL).  
Patients will be treated for 84 days and randomized into one of two groups in a 1:1 ratio: 
• TAVT -45:  Administered  twice daily as 1 x sachet TAVT -45(250 mg abir aterone acetate)  
+ Prednisone (5 mg once or twice daily, depending on prostate cancer population)  
• R-AA: Administered once daily as 2 x 500 mg Zytiga tablets + Prednisone (5 mg once or 
twice daily, depending on prostate cancer population)  
 
 
Figure 1                       Study s chema   
 
 
 
It is planned to enroll 108 patients in this study  (n=54 patients per prostate cancer population), 
randomized in a 1:1 ratio receiving either TAVT -45 (n=27 mCRPC and n= 27 mCSPC patients) 
or R-AA (n= 27 mCRPC and n= 27 m CSPC patients).  
3.2 Rationale for study design  
Because this study will administer TAVT -45 at 250 mg BID, while maintaining the standard 
approved dosing of once daily R -AA (i.e., 1000 mg QD), as discussed below, it is not possible to 
directly compare the PK profile between these two agents using a tradi tional bioequivalence of 
Cmax and AUC.  Therefore, this study aims to establish therapeutic equivalence of clinical efficacy 
and safety.  
This study will evaluate serum testosterone levels after treatment with TAVT -45 compared to 
R-AA as the primary efficacy endpoint to show equivalent pharmacodynamic effects. 
Testosterone suppression has been recognized by the FDA as an appropriate efficacy endpoint for 
establishing efficacy of GnRH agonists and antagonists that are  approved after the 

Confidential  
EudraCT 2020 -005611 -46 Page 28 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 originator/prototype agents . Using serum testosterone as the primary endpoint for clinical 
equivalence is  also consistent with the study design used in the STAAR study, which was a 
randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulatio n 
(Yonsa®)  vs. originator abiraterone acetate (Zytiga) in patients with m CRPC [ 15]. Like the 
STAAR study, this study will also assess serum testosterone on Days 9 and 10 of treatment, which 
aligns with the expected attainment of steady state a biraterone  plasma concentrations. The safety 
and tolerability profiles will also be examined, togethe r with other measures of efficacy, including 
PSA, which is the key secondary efficacy endpoint that will provide further supportive evidence 
of the clinical similarity between TAVT -45 and R -AA. 
The two study populations, mCRPC and m CSPC , will be randomized in a 1:1 ratio to ensure 
balance of the populations across the two treatment groups.  Likewise,  randomization will be 
stratified by baseline testosterone levels (< 10 and ≥ 10 ng/ dL) to ensure balance in each treatment 
arm.  The testosterone str atification threshold of 10 ng/ dL was selected considering the baseline 
levels report ed in the STA AR study for the  patients with mCRPC  [15] as well as average 
testosterone values observed following bilateral orchiectomy [ 16]. 
3.3 Rationale for dose/regimen, route of administration and duration of  
treatment  
The dose level of R -AA for this study is 1000 mg once daily, which is the standard approved dose 
level [ 3].  
The dose level of TAVT -45 will be 250 mg BID , which corresponds to a total daily dose of 
500 mg. Selection  of this dosing regimen is supported by single dose data from the Phase 1 PK 
study DRGT45C03 (see also Section 1.3.2.3 for details) . One of the aims of Part 2 of this study 
was to have an in -study comparison between DRGT -45 and R -AA for PK bioequivalence 
assessments after single doses . Of specific interest was to evaluate whether abiraterone exposure 
after 250 mg DRGT -45 dosing was at least PK bioequivalent or higher than the lower limit (i.e, 
1000 mg R -AA under fasted conditions) and at most PK bioequivalent or lower than the upper 
limit (i.e., 1000 mg R-AA und er modified fasted conditions). Key findings are summarized below:  
• Lower Limit:  Following administration of 250 mg DRGT -45 in the fed state, peak 
exposure (C max) was approximately equivalent to or moderately higher than that of 
1000 mg R -AA in the fasted state, while overall exposure (AUC 0-last and AUC 0-∞) was 
approximately equivalent to or moderately lower. Similar findings were observed following 250 mg DRGT -45 in the fasted state, whereby peak exposure was greater than 
that of 1000 mg R -AA in the  fasted state and overall exposure was equivalent to or greater.  
• Upper Limit:  When compared to that of 1000 mg R -AA dosed in the modified fasted state, 
representing an upper safety limit for the exposure range, both peak and overall exposure levels after D RGT -45 dosing were notably less than the reference regimen (relative 
bioavailabilities for C
max and AUC ranged from approximately 14- 38%). The gap that 
exists between DRGT -45 exposure, regardless of prandial state dosed, and the upper end 
of Zytiga exposur e, highlights that there is a wide safety- related exposure margin for future 
increases in DRGT -45 dose or modification in dose regimens (e.g., BID dosing). 
• Simulations of BID Dosing:  Simulation of repeat ed dosing w as also performed based on 
the single dose  PK data. The predicted plasma concentrations and exposures after dosing 
with DRGT -45 250 mg BID fell within the range observed for R -AA 1000 mg QD at 
steady -state. Based on low trough concentrations at 12- hours post -dose, Cmax is predicted 
to be only slightly increased in steady state (5 -10%) for DRGT -45 250 mg BID . 
Confidential  
EudraCT 2020 -005611 -46 Page 29 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 In the study described herein, R-AA will be administered orally  either ≥ 1 hour before or ≥ 2 hours 
after a meal .  TAVT -45 will be administered without respect to food with the exception of dose 
administration in the pharmacokinetic sub- study.  Patients participating in the serial blood draws 
on Days 1 and 9 will administer TAVT -45 in the fasted state  (minimum of 8 h fast)  on these days  
and may resume normal meal schedules 2 h af ter administration of the TAVT -45. 
The duration of treatment in this study will be 84 days  (12 weeks) . This is equivalent to three 
28-day cycles , and consistent with the STAAR study that also compared a novel abiraterone 
formulation to R -AA [15]. Moreover, 12 weeks is a time point that is historically used in many 
metastatic CRPC studies as a landmark for measuring response to therapy; for example, PSA 
responses at 12 weeks was a statistically significant factor associated with survival in a 
multivariate analysis using a prognostic model applied to multiple clinical trials [ 17,18].  
For the dose selection and timing of the concomitant prednisone, see Section 3.5.  
3.4  Formulation to be used  
This study will use TAVT -45 and R -AA (which is the reference abiraterone acetate currently 
marketed under the trade name Zytiga).  
Abiraterone acetate is the acetyl ester of abiraterone, which is an inhibitor of CYP17.  The 
chemical designation is 3β -acetoxy -17-(3-pyridyl) -androsta -5,16-diene .  It is a white to off -white 
powder practically insoluble in aqueous media (pH range 2.0 to 12.9), very slightly soluble in 
0.1N HCl solution and soluble to freely soluble in organic solvents. Abiraterone acetate is classified as Class IV compound  (low solubility low permeability) according to the 
biopharmaceutical classification system (BCS).  Its empirical formula is C
26H33NO 2. The 
structural formula is  shown in Figure 2.  
 
Figure 2                       Structural formula of the study drug ( abiraterone acetate)  
 
 
R-AA tablets are available as film- coated tablets containing 500 mg a biraterone acetate and as 
uncoated tablets containing 250 mg. The excipients used in the formulation of Zytiga  are lactose 
monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate and colloidal silicon dioxide .  
TAVT -45 granules  contain 3.83% abiraterone acetate as active ingredient along with 19.13% 
Plasdone K12, 0.03% BHT and 0.03% BHA, 15.31% Soluplus, 0.50% Aerosil 200, 2.30% 
Sodium deoxycholate, 23.27% Microcrystalline cellulose, 21.36% Lactose/Lactose monohydrate, 
11.63% Crospovidone , 2.00% PEG4000, 0.43% Sodium stearyl fumarate and 0.20% Saccharin 
Sodium as excipients.  

Confidential  
EudraCT 2020 -005611 -46 Page 30 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 3.5 Rationale for choice of additional treatment  
In addition to the TAVT -45 or R -AA treatments, all patients in this study will also receive 
prednisone during the treatment period. Specifically, 5 mg prednisone will be administered orally 
twice daily for m CRPC patients, and 5 mg prednisone orally once daily will be administered fo r 
mCSPC patients.  
This requirement for co -adminstration of prednisone (including the dose level and frequency for 
mCRPC and m CSPC patients ) is consistent with the on -label dosing requirements on R -AA. 
Abiraterone is a CYP17A1 inhibitor , and one of the side  effects of CYP17A1 inhibition is a 
decrease in cortisol levels . This leads to a compensatory increase in adrenocorticotropic hormone 
(ACTH), and an accumulation of steroids with mineralocorticoid properties.  Glucocorticoids, 
such as prednisone , can suppr ess ACTH secretion from the anterior pituitary and thus prevent 
mineralocorticoid -related side effects  (e.g., hypokalemia, hypertension, and fluid retention ).   
As part of the standard ADT  background, all patients in this study must also be receiving a GnRH 
analog concurrently if they have not had a bilateral orchiectomy.  ADT background will be 
recorded in the CRF.  Patients receiving a GnRH analog will record administration in a diary to allow assessment of compliance with ADT therapy.  
3.6 Purpose and timing of interim analyses/design adaptations  
Not applicable as there are no plans for conducting an interim analysis.   
3.7 Risks and benefits  
Since R -AA is already approved by the FDA for both mCRPC and mCSPC with distant 
metastases, and TAVT -45 contains the same active ingredient (abiraterone acetate), it is expected 
that patients will benefit from these treatments. Additional potential benefits of TAVT -45 over 
R-AA are described in Section 1.4, and may include less  variability of exposure, no requirement 
to take the drug on an empty stomach, and an alternative choice for patients with dysphagia or aversion to swallowing large pills. 
There is considerable data available on the adverse effects associated with abiraterone acetate 
from placebo -controlled clinical trials (comprising  over 2000 patients from the Zytiga clinical 
program) ; full details are available in the Zytiga  SmPC [ 4]. 
Based on pooled safety analyses of multiple clinical trials [ 3,4], t he most common adverse  
reactions  (≥10%) that occurred more commonly (>2%) in Zytiga treatment arm compared to 
placebo were fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, 
vomiting, upper respiratory infection, cough, and headache.  The most common laboratory 
abnormalities (>20%) that occurred more commonly (≥2%) in the  Zytiga  arm were anemia, 
elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hyper cholesterolemia, 
hyperglycemia, and hypokalemia. Grades 3- 4 adverse events were reported for 53% of patients in 
the Zytiga arm and 46% of patients in the placebo arm.  Treatment discontinuation was reported 
in 14% of patients  in the Zytiga arm and 13% of p atients in the placebo arm.  The common adverse 
events (≥1%) resulting in discontinuation of Zytiga  and prednisone were hepatotoxicity and 
cardiac disorder . 
Since TAVT -45 also contains abiraterone acetate as the active ingredient, any adverse reactions 
and their incidences are expected to be similar to those reported for Zytiga.  
One of the excipients (Soluplus) in the TAVT -45 granules has been shown to cause pseudo allergy 
symptoms in dogs given single dos es, therefore this excipient may also have the potential to cause 
allergy -like reactions in humans  [19]. 
Confidential  
EudraCT 2020 -005611 -46 Page 31 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 General Risks  
During cannulation, more than one attempt may be needed to insert the cannula in a vein of a 
patient,  and it is possible that bruising and/or inflammation may be experienced at the site of 
cannulation.  
COVID- 19 Related Risks  
The following risks and risk mitigating measures apply to this study which may be impacted by 
the ongoing SARS -CoV -2 (COVID -19) global  pandemic:  
• Test Product Related Risk:    
o Based on a review of both nonclinical and clinical data, neither Zytiga nor TAVT -45 have immunomodulatory effect s that would confer an increased risk to 
participants enrolled in the study  either contracting or experiencing a more serious 
disease if infected with COVID -19.   
• General COVID -19 Related -Risk Mitigation Measures: 
o Tavanta and the clinical CRO ( TMC ) will work with clinical sites to document 
site-level procedures regarding COVID -related precautions for patients and staff 
(such as personal protective devices of face coverings, masks,  shields , temperature 
screening, and social distancing procedures).  T he study visit schedule has also 
been carefully reviewed to minimize unnecessary visits and patient exposure. 
o Tavanta and TMC will continue to assess risk during the course of the clinical 
study  due to COVID -19 impact. This includes risk assessment for the overall 
study, as well as at the country/regional levels since changes/adaptations may be needed at a local level depending on the local COVID -19 situation. This may 
include impacts on visit sc hedules, assessments performed in -person or virtually, 
and alternative options for IMP re -supply for patients. T avanta and TMC will also 
communicate as needed with IRB/IEC and Data Monitoring Committee (DMC) staff.  The risk mitigation measures, where appl icable, will be amended based on 
emerging government guidances.  
4 STUDY POPULATION  
The study population will consist of  mCSPC and m CRPC patients . 
The study population will be comprised of the patients  who have passed screening assessments 
and who comply with eligibility criteria. Screening procedures can be repeated once to confirm 
out of range values prior to excluding a patient from participating in the study. Patients  can be re-
screened only once, and no study related re -screening procedures should be perf ormed before re-
consent by the patient . Mis -randomized patients  will not be re -screened.  
4.1 Inclusion Criteria  
1. Written informed consent obtained prior to any study- related procedure being performed  
2. Male patients at least 18 years of age or older at time of consent  
3. Pathologically confirmed adenocarcinoma of the prostate  
4. Ongoing therapy with a gonadotropin releasi ng hormone (GnRH) agonist or antagonist (unless 
patient has already had a bilateral orchiectomy) AND serum testosterone level <50 ng/dL at screening  
Confidential  
EudraCT 2020 -005611 -46 Page 32 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 5. Have either metastatic CSPC or metastatic CRPC, as defined below:  
• CSPC:    Using the American Joint Committee on Cancer (AJCC) tumor, node, 
metastasis (TNM) system, patients must have T any Nany M+ (distant metastases) 
disease AND two of the following:  
• Gleason score of 8 or greater  
• Three or more bone scan lesions 
• Measurable visceral metastases  
• CRPC: Patients must have metastatic* disease, and must also have disease progression 
according to the recommendations of the Prostate Cancer Working Group 3 by having 
at least one of the following criteria:  
• Two rises of PSA (taken a minimum of 1 week apart) from a baseline 
measurement of at least 1 ng/mL  
• Imaging progression (CT/MRI) by RECIST 1.1 criteria or PET/CT* 
• Nuclear scan progression by 2 or more new bone lesions. 
* Note:  Metastatic disease should be documented by MRI/CT, PET/CT (including, but not 
limited to, standard of care imaging using 18F-fluciclovine, 11C-choline, or PSMA where 
approved) or bone scan. Imaging obtained within 90 days prior to the start of study  
drug/reference product will be accepted . 
6. The following prior treatment and / or surgery for prostate cancer are allowed:  
• CSPC :    
• Up to 90 days of androgen deprivation therapy (ADT) with gonadotropin-
releasing hormone ( GnRH) agonists /antagonists or orchiectomy with or 
without concurrent anti -androgens prior to patients’ randomization is permitted 
• Patients may have one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease (e.g., impending cord compression or obstructive symptoms) if administered prior to randomization 
• Radiation or surgical therapy that was not initiated 4 weeks after the start of 
ADT or orchiectomy  
• CRPC: 
• Previous chemotherapy with docetaxel for metastatic disease with treatment 
completed at least 1 year prior to Screening  
7. Discontinuation of flutamide or nilutamide , and other anti -androgens prior to the start of study 
medication; discontinuation of bicalutamide prior to start of study medication  
8. Discontinuation of strong CYP3A 4 inducers at least 4 weeks  prior to start of study medicatio n 
9. Discontinuation of radiotherapy prior to start of study medication  
10. Discontinuation of herbal supplements at least 4 weeks  prior to the first dose of study 
medication and for the duration of the trial.   
11. Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 at screenin g  
Confidential  
EudraCT 2020 -005611 -46 Page 33 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 12. Normal organ function with acceptable initial laboratory values within the screening period :  
ANC  ≥ 1,500/µl  
Albumin  
Hemoglobin  ≥ 3.0g/dL 
 ≥ 9g/dL 
Platelet count   ≥ 100,000/µl 
Serum 
Creatinine  ≤ 3.0 x the institutional upper limit of normal 
(ULN)  
Potassium > 3.5 mmol/L (within institutional normal 
range)  
Bilirubin  ≤ 1.5 ULN (unless documented Gilbert's 
disease)  
SGOT (AST)  ≤ 2.5 x ULN  
SGPT (ALT)  ≤ 2.5 x ULN 
13. Life expectancy of at least 6 months at screening  
14. Patients engaged in sex with women of child- bearing potential agree to use a condom plus 
another effective contraception method.  Patients agree to use a condom when engaged in any 
sexual activity, including sex with a pregnant woman. These restrictions will apply from the time informed consent is provided until  3 weeks after the last dose of study medication is 
taken.   
15. Patient is willing and able to comply with all protocol requirements assessments  
4.2 Exclusion criteria 
1. For mCSPC patients:  
• Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer not specified as allowable treatment in Inclusion Criterion 6. For example, 
prior therapy with apalutamide or enzalutamide is prohibited as well as therapy with an investigational agent as described in Exclusion Criterion 16. 
2. For mCRPC patients:  
• Prior treatment with abiraterone or enzalutamide  is prohibited 
• Previous chemotherapy is prohibited with exception of docetaxel treatment as specified in 
Inclusion C riteri on 6. 
3. Initiation of bisphosphonate or denosumab therapy within 4 weeks  prior to the start of study 
drug/reference product. Patients who are on a stable dose of these medications for at least 4 week s at the time of starting study drug/reference product will be eligible. 
4. Therapy with estrogen within 4 weeks  prior to the start of study drug 
5. Use of systemic glucocorticoids equivalent to >10 mg prednisone daily. Patients who have discontinued or reduced dosing to the equivalent of ≤ 10 mg prednisone daily within 14 days 
prior to the start of study drug are eligible 
6. Known, symptomatic metastases to the brain or central nervous system involvement (patients with asymptomatic and neurologically stable disease for the past 4 weeks will be permitted)  
7. History of adrenal gland dysfunction defined as requiring treatment for adrenal insufficiency 
8. History of other malignancy within the previous 2 years (no longer being actively treated), with the exceptions of basal cell carcinoma, non -muscle invasive bladder cancer that has been 
treated and is under surveillance, or other in-situ cancers with a low likelihood of recurrence  
9. Major surgery within 4 weeks  prior to the start of study drug 
Confidential  
EudraCT 2020 -005611 -46 Page 34 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 10. Known gastrointestinal disease or condition that could impair absorption inclusive of 
gastrocolic fistula, gastroenterostomy, biliary obstruction, cirrhosis, chronic pancreatitis or 
pancreatic cancer, cystic fibrosis, lactate deficiency, amyloidosis, celiac disease, Crohn’s disease, radi ation enteritis, intestinal resection, and history of bariatric surgery  
11. Known history of human immunodeficiency virus or seropositive test for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) (note: HCV patients with undetectable viral load w ill be eligible)  
12. Poorly controlled diabetes, defined as HbA1c  > 8% within the past 12 months   
13. Uncontrolled hypertension at screening  
14. History of New York Heart Association class III or IV heart failure  
15. Serious concurrent illness, including psychiatric illness, that could interfere with study participation  
16. Receipt of another investigational agent within 4 weeks or 5 x the treatment half -life, 
whichever is longer , of treatment start.  
17. Known hypersensitivity or allergy to abiraterone acetate, pr ednisone  or any excipients in the 
study drugs  
18. In the opinion of the investigator, participation in the trial would prevent the patient from receiving local standard -of-care treatment for metastatic prostate cancer, if clinically 
indicated, after completion of the trial   
19. Other condition which, in the opinion of the Investigator, would preclude participation in this trial. 
5 TREATMENT 
5.1 Study treatment: investigational and control drugs  
Tavanta will supply the following study drug:  
Investigational treatment  
•   TAVT -45 (250 mg abiraterone acetate) -  Granule s for O ral Suspension 
Tavanta will supply the reference treatment which will be centrally sourced and supplied. 
Reference treatment  
•   R-AA (reference abiraterone acetate [Zytiga ]) 500 mg tablets  
5.2 Additional treatments 
In addition to the study drugs described above in Section 5.1, Tavanta  or designee will also supply  
prednisone  (5 mg tablets).  Specifically, 5 mg prednisone will be administered orally twice daily 
for mCRPC patients, and 5 mg prednisone orally once daily will be administered for m CSPC 
patients.  
All patients must also be receiving a GnRH analog concurrently if they have not had a bilateral orchiectomy.  GnRH analogs will not be provided by T avanta and will be sourced locally through 
the patient’s current prescription. 
Confidential  
EudraCT 2020 -005611 -46 Page 35 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 5.3 Treatment arms  
In this study, patients will be randomized 1:1 to one of two groups and treated for 84 days: 
• TAVT -45:  Administered twice daily as 1 x sachet conta ining TAVT -45 granules (250 mg 
abiraterone acetate) + Prednisone (5 mg once or twice daily, depending on prostate cancer 
population) 
• R-AA once daily:  Ad ministered once daily as (2 x 500 mg Zytiga tablets) + Prednisone 
(5 mg once or twice daily, depending on prostate cancer population ) 
5.4 Treatment assignment and randomization 
All eligible patient s will be randomized  1:1 to one of the two treatment arms .  Randomization will 
be stratified by prostate cancer population (CSPC vs CRPC; n= 54 per cancer population) and 
baseline testosterone (<10 vs ≥ 10 ng/ dL). 
Patients will be assigned a Subject Number  upon screening. Eligible patients will be randomized 
via an Interactive Response Technology (IRT) system. Sites will contact the IRT system only after  
confirming all eligibility c riteria and receiving the screening testosterone value that is needed for 
stratification  (see Table 1). The IRT will assign the patient to  the appropriate treatment arm and 
provide a medication number  that will be linked to the different treatments . A separate medication 
list will be produced by or under the responsibility of T avanta using a validated system that 
automates the random assignment of medication numbers to packs containing the study drug(s).  
5.5 Treatment blinding 
This study is open label.  
5.6 Treating the subject 
5.6.1  Subject numbering 
Each patient  is uniquely identified by a Subject Number. Once assigned to a patient , the Subject 
Number will not be reused. Patient s may be re- screened once. In this case, the IRT  can be used to 
request the initial Subject Number in order to link  the re- screening to the original screen of that 
patient . Patient s who are mis -randomized cannot be re-screened.  
5.6.2  Dispensing the investigational treatment 
Each study site will be supplied by T avanta or designee with sachets containing TAVT -45 and R -
AA table ts. A unique medication number is printed on each part of the label which corresponds 
to test  or reference  treatment.  
5.6.3  Handling of study treatment 
Study Investigational treatment must be received by a designated staff member at the study site, 
handled and stored safely and properly, and kept in a secured location. Upon receipt, all investigational treatment should be stored according to the instructions specified on the labels.  
TAVT -45 granules should be stored at room temperature in the  aluminum foil sachet . R-AA 
tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted in the range from 15°C to 30°C (59°F to 86°F). Clinical suppl ies are to be dispensed only in accordance with the 
protocol. Any  excursions or lack of compliance should be reported  to Tavanta or designee. 
Medication labels will include storage conditions for the study treatment and  the medication 
number and will be co mpliant with labeling regulations. 
Confidential  
EudraCT 2020 -005611 -46 Page 36 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 The qualified site personnel must maintain an accurate record of the shipment and dispensing of 
study treatment. Monitoring of drug accountability will be performed by a  field monitor during 
site visits and at the completion of the  trial. At the conclusion of the  study and as appropriate 
during the study, all investigational treatments will be reconciled  at the site and depot level. 
Instructions for the final disposition of all unused study medication will be provided to e ach site 
in advance of site closure.   
5.6.4  Instructions for prescribing and taking study  treatment  
Study treatments TAVT -45 and R-AA [Zytiga ] tablets ) will be administered orally each day from 
Day 1 to Day 84.  
TAVT -45 will be taken twice daily (approximately every 12 hours ) and  may be taken without 
respect to meals.  An exception applies to those patients included in the serial pharmacokinetic 
cohort.  Patients participating in the serial blood draws on Days 1 and 9 will administer TAVT -45 
in the fasted state  (minimum of 8 h overnight fast) on these days and may resume normal meal 
schedules 2 h after administration of the TAVT -45 on these days.   
Each TAVT -45 sachet  contains 250 mg abiraterone acetate, and e xcipients  that ensure abiraterone 
acetate disperses instantaneously in water  or specified juice . For a 250 mg dose , 1 granule sachet  
should be reconstituted  in tap water  or specified juice and the resulting suspension immediately 
administered  orally. Reconstitution of the granules  can be obtained by stirring the suspension with 
a spoon for 3 minutes . The reconstituted suspension should be taken immediately  after 
reconstitution .  Patients will receive training and a medication preparation guide  to ensure correct 
preparation and administration. At visits when trough abiraterone samples are obtained (see Table 
1), the reconstitution fluid (water or juice) used for the last dose will be recorded in the eCRF.  
For R -AA, t ablets should be  taken once daily, either ≥ 1 hour before or ≥ 2 hours after a meal , and  
swallowed  whole with water . For a 1000 mg dose, 2 tablets (containing 500 mg abiraterone 
acetate) should be taken together.  
Patients will be instructed to record administration of study medications  in a dosing diary.  This 
is inclusive of TAVT -45, R -AA, prednisone and GnRH  analog, if applicable.  The patient will  
record the date and time of each administration of each medication .  For TAVT -45, the patient 
will also record the fluid (water or specified juice) used for reconstitution. 
The investigator should promote compliance by instructing the patient  to attend th e study visits as 
scheduled and by stating that compliance is necessary for the patient ’s safety and the validity of 
the study. The patient  should be instructed to contact  the investigator if he is unable for any reason 
to attend a study visit as scheduled.  
5.6.5  Permitted dose adjustments and interruptions of study  treatment  
There will not be any planned permitted adjustments of dose strength and frequency.  Patients 
should take TAVT -45 and R -AA as per protocol.  
However, if needed due to adverse events, study medication may be temporarily or permanently 
discontinued at the discretion  of the Investigator  based on the  toxicity management guidance 
described below related to hepatotoxicity and Grade ≥ 3 toxicities , which align s with Zytiga 
prescribing information [ 3, 4]. Investigators should consult with the Medical Monitor for 
questions /clarifications as needed.   
• Hepatotoxicity :  If at any time  during the trial, the ALT or AST rises above 5 x ULN, or 
total bilirubin  rises above 3x ULN, treatment with TAVT -45 or R -AA should be 
discontinued immediately and the patient should be discontinued from the study. As noted 
Confidential  
EudraCT 2020 -005611 -46 Page 37 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 above, dose reductions are not applicable for this clinical trial, as only one strength of each 
study medication (TAVT -45 and R -AA) are supplied to patients. L iver function should be  
closely monitored as part of adverse event monitoring. 
• Grade ≥ 3 toxicities of hypertension, hypokalaemia, oedema and other non-mineralocorticoid toxicities:  If at any time during the trial, a patient experiences Grade ≥ 
3  hypertension, hypokalaemia, oedema or  other non- mineralocorticoid toxicities  
(according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events [CTCAE], Version 5.0 [20]), treatment should be withheld and appropriate medical 
management should be instituted. Treatment with TAVT -45 or R -AA should not be 
reinitiated until symptoms of the toxicity have resolved t o Grade 1 or baseline .  
All actions with respect to study drug dosing in relation to an AE must be documented appropriately within the CRF. 
5.6.6  
Rescue medication  
Not applicable.  
5.6.7  Concomitant  medication  
In addition to the TAVT -45 or R -AA treatments, all patients in this study will also receive 
prednisone during the treatment period. Specifically, 5 mg prednisone will be administered orally twice daily for m CRPC patients and 5 mg prednisone orally once daily will be administered for  
mCSPC patients.  
Per protocol, a ll patients in this study should also be taking a GnRH analog concurrently or should 
have had bilateral orchiectomy. 
Bisphosphonate usage is allowed only if patients are on the medication at a stable dose and 
regimen for 4 weeks  prior to Study Day 1 (see E xclusion C riteri on #3) . 
The investigator should instruct the patient  to notify the study site about any new medications 
over-the-counter drugs, supplements, and vitamins administered after the patient  is enrolled into 
the study. All medications (other than study treatment), procedures and significant non- drug 
therapies (including physical therapy and blood transfusions) must be recorded on the CRF. The 
reason, name of the drug, procedure or non- drug therapy should be listed.  
Since androgen deprivation treatment may prolong the QT interval, caution is advised when 
administering abiraterone acetate with medicinal products known to prolong the QT interval or 
medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. 
Use of spironolactone with abiraterone acetate is not recommended, since spironolactone binds to 
the androgen receptor and may increase PSA levels.  
5.6.8  
Prohibited medication (interaction with other medicinal products 
and other forms of interaction)  
Refer to the Inclusion and Exclusion Criteria regarding medications that are prohibited , or must 
be discontinued, prior to th e start of study drug and throughout the study (see Section s 4.1 and 
4.2). 
Confidential  
EudraCT 2020 -005611 -46 Page 38 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Concomitant use of a strong CYP3A 4 inducer should be avoided (see Section 5.6.8.2)  and caution 
should be exercised if a CYP2D6 substrate with a narrow therapeutic index cannot be avoided 
(see Section 5.6.8.3).  
5.6.8.1  Abiraterone acetate contraindicat ions 
Abiraterone acetate can cause fetal harm and potential loss of pregnancy based on animal studies. 
However, it is not indicated for use in wome n.   
5.6.8.2  Effects of other m edicinal products on abiraterone acetate   
Cytochrome P450 inhibitor  
In a dedicated drug interaction trial, co -administration of ketoconazole, a strong inhibitor of 
CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone . 
Cytochrome P450 inducers  
In a dedicated drug interaction trial, co -administration of rifampin, a strong CYP3A4 inducer, 
decreased exposure of abiraterone by 55%. This reduced exposure can be anticipated to decrease 
the efficacy of abiraterone. Thus, concomitant strong CYP3A4 inducers should be avoided during abiraterone treatment. Notable examples of strong CYP3A4 inducers are apalutamide, 
carbamazepine,  enzalutamide, mitotane, phenobarbital , phenytoin, rifabutin, rifampicin, 
rifapentine and St John's wort  [4,21] . 
5.6.8.3  Effects of abiraterone acetate on other medicinal products  
CYP2D6 Substrate  
Abiraterone is an inhibitor of the hepatic drug- metabolizing enzyme CYP2D6.  In a CYP2D6 
drug- drug interaction trial, the C
max and AUC of dextromethorphan (CYP2D6 substrate) were 
increased 2.8 - and 2.9- fold, respectively, when dextromethorphan was given with abiraterone 
acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co- administration of abiraterone 
acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine).  If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug.  
CYP2 C8 Substrate  
Abiraterone is an inhibitor of the hepatic drug- metabolizing enzyme CYP2 C8.  In a CYP2C 8 
drug- drug interaction trial, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% 
when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate.  
Ther efore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate 
with a narrow therapeutic index if used concomitantly with abiraterone.  Investiga tors may consult 
with the M edical Monitor for identification of CYP2C8 substrates with narrow therapeutic index.   
5.6.9  
Discontinuation of study treatment  
Patient s may voluntarily discontinue study treatment or the study for any reason at any time. The 
investigator should discontinue study treatment for a patient  if, on balance, he/she believes that 
continuation would be detrimental to that patient ’s well-being. Study treatment must be 
discontinued under the following circumstances:  
• Withdrawal of informed  consent  
• Patient ’s request to terminate  treatment  (in this case, the patient may choose to discontinue 
study treatment, but remain in the study to be followed for safety and undergo study procedures through the follow -up period)  
Confidential  
EudraCT 2020 -005611 -46 Page 39 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 • Any AE, clinically relevant change(s) in a safety parameter, or other medical condition or 
situation that occurs such that continued participation in the study would not be in t he 
participant’s best interest. This includes ALT or AST rises above 5x ULN, or total bilirubin rises above 3x ULN , at any  time during the study as described in Section 5.6.5. 
• Use of prohibited treatment  without approval from the Medical Monitor   
• Any other protocol deviation that results in a significant risk to the patient ’s safety  
• Study is terminated by the S ponsor or local health authority, IRB, or IEC
 
For patient s who discontinue study treatment, a CRF should be completed, giving the date and 
primary reason for stopping study treatment.  In the event that the decision is made to permanently 
discontinue the study treatment, the patient will be withdrawn, and the ET visit should be 
conducted. Reasonable efforts should be made to have the patient return for this follow -up visit.  
5.7 Withdrawal of consent  
Patient s may be considered discontinued if they state an intention to withdraw, fail to return for 
visits, or become lost to follow -up for any other reason. 
If premature discontinuation occurs for any reason, the investigator must make every effort to determine the primary reason for a patient ’s premature discontinuation from the study and record 
this information on the CRF. Patient s may voluntarily withdraw c onsent to participate in the study 
for any reason at any time. 
Withdrawal of consent occurs when a patient  does not want to participate in the study anymore, 
that is, the patient  does not want any further visits, assessments, or study- related contact and d oes 
not allow analysis of already obtained biologic material. Study treatment must be discontinued,  
and no further assessments conducted. All biological material that has not been analyzed at the 
time of withdrawal must not be used. Further attempts to contact the patient  are not allowed unless 
safety findings require communicating or follow -up. The data collected on the patient  to the point 
of withdrawal remains part of the study database and may not be removed.
 
5.8 Lost to follow-up  
For patient s whose status is unclear because they fail to appear for study visits without stating an 
intention to withdraw, the investigator should show "due diligence" by contacting the patient , 
family or family physician as agreed in the informed consent and by documenting in the  source 
documents steps taken to contact the patient , e.g. dates of telephone calls, registered letters, etc. 
A patient  should not be formally considered lost to follow -up until his scheduled End- of-Study 
visit would have  occurred.  
5.9 Emergency breaking of assigned treatment code  
Not applicable as the study is open label . 
5.10 Study completion and post-study treatment  
End of study is defined as the date of the last patient last visit (i.e., the Visit 10 follow -up phone 
call for patients completing the trial as plan ned, or the Early Termination Visit for patients who 
are treated but discontinue prior to completing the Day 84 visit [see Table 1  below]).  
Information on the patient ’s completion of dosing during the  Treatment Period, or premature 
discontinuation and the reason for discontinuation will be recorded on the appropriate form  of 
CRF.  In any case, the investigator or site staff must contact as soon as possible to record the 
patient ’s study completion and/or discontinuation. 
Confidential  
EudraCT 2020 -005611 -46 Page 40 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 The investigator must provide follow -up medical care for all patient s who are prematurely 
withdrawn from the study or  must refer them for appropriate ongoing care. This care may include 
initiating another treatment outside of the study as deemed appropriate by the investigator.  
There is no post -trial access to  study medication after patients complete this trial; instead 
investigators  will prescribe the local standard- of-care treatment for metastatic prostate cancer , if 
clinically indicated . 
5.11 Early study termination  
The study can be terminated at any time for any reason by T avanta. Should this be necessary, the 
patient  must be seen as soon as possible and treated as a prematurely withdrawn patient . The 
investigator may be informed of additional procedures to be follow ed in order to ensure that 
adequate consideration is given to the protection of the patient ’s interests. The investigator will 
be responsible for informing the Institutional Review Board (IRBs) or Independent Ethics 
Committee (IECs) of the early terminatio n of the trial. 
6 VISIT SCHEDULE AND ASSESSMENTS  
Table 1 lists all of the assessments and indicates with an “ X” when the assessments should be  
performed  at the designated time points . Patient s should be seen for all visits on the designated 
day or as closely as possible to the original planned visit schedule. Missed or rescheduled visits should not lead to automatic discontinuation. 
If patient s refuse to return for these assessments or are unable to do so, every effort should be 
made to contact them or a knowledgeable informant by telephone to determine the reason. 
Attempts to contact the patient  should be recorded in the source documentation. 
Screening will be flexible in duration of up to 28 days before first dosing, during which time the 
patient  will sign the informed consent form (ICF)  to participate in the study before any protocol -
specified procedures or assessments are initiated . Patients  evaluated at screening for eligibility 
should not be screen failed on the basis of a medication requiring washout, unless the patient will be unable to complete the washout in the appropriate time frame before randomization.  Upon meeting all inclusion/ex clusion criteria set forth in the protocol, patients will be randomized in a 
1:1 fashion to receive either TAVT -45 250 mg twice daily  (approximately every 12 hours) or 
R-AA 1000 mg once daily either ≥ 1 hour before or ≥ 2 hours after a meal. All patients s hould 
also receive prednisone together with a gonadotropin- releasing hormone (GnRH) analog 
concurrently or should have had bilateral orchiectomy. The  mCSPC patients will receive 
prednisone 5 mg orally once daily, while the m CRPC patients will receive predn isone 5 mg orally 
twice daily.  Randomization will be stratified by prostate cancer population (CSPC vs CRPC) and 
baseline testosterone (<10 vs ≥ 10 ng/ dL). All patients will be treated for 84 days (12 weeks) .  
Patients will return to their clinics on Days  9, 10, 28, 56 and 84 for assessments and evaluations 
of safety and efficacy, including testosterone , PSA, and abiraterone trough concentrations . 
Patients  may return to the clinic or may visit a local laboratory for evaluation of liver function 
tests on Da ys 42 and 70.  Blood samples for testosterone will be taken between the hours of 7- 10 
in the morning. A pharmacokinetic sub- study will be conducted in a cohort of up to 8 patients 
receiving TAVT -45. Pharmacokinetic profiles  over the dosing interval  will be obtained on Day 1 
(first dose) and on Day 9 ( steady state ).  For all patients, a  follow -up phone call will also be made 
approximately one week after the last dose for AE assessments .  
Confidential  
EudraCT 2020 -005611 -46 Page 41 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
      
 
Table 1                      Assessment schedule  
 Screening  
(Day -28  
to -1) Day 1  Day 9  
(+2) Day 10  
(+2) Day 28 
(+/-1) 
 Day 42 
(+/- 3) Day 56   
(+/-1) 
 Day 70  
(+/- 3) Day 84  
  (+/-1) 
 Follow -up 
Visit1 
(Day 91 
(+/-4) Early 
Termination 
(ET) Visit2 
Visit number  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET 
Informed consent  X           
Inclusion/Exclusion criteria  X X          
Demography  X           
Medical history/diagnosis  X X          
Physical examination3 X3 X   X  X  X  X 
ECOG  X X   X  X  X  X 
12-lead ECG4 X           
Vital signs  X X X  X  X  X  X 
Body weight  and height5 X5 X   X  X  X  X 
Clinical laboratory tests6 X6 X X  X  X  X  X 
Hepatotoxicity Monitoring7    X  X  X    
Serum testosterone8 X X X X X  X  X  X 
PSA8 X X   X  X  X  X 
Serial Pharmacokinetic Sampling9  X X         
Abiraterone trough 
concentrations10   X  X  X  X   
Prior/concomitant medication  X X X X X X X X X X X 
Adverse Events/ SAEs11  X X X X X X X X X X 
Randomization  X12  
         
Drug dispensation   X   X  X     
Drug return/compliance /diary 
review       X  X  X  X 
 
  
Confidential  
EudraCT 2020 -005611 -46 Page 42 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
  
 
 
1. For the follow -up visit, a phone call should be made approximately one week after the last dose for AE assessments  
2. If patients are randomized and t reated, but discontinue prior to completing the Day 84 visit,  then an early termination visit should be scheduled.  
3. Physical examination at screening includes examination of general appearance, skin, lungs, heart, abdomen, lymph nodes, extremities and vascular system.  Abbreviated 
examinat ions thereafter to include targeted assessment(s) of the body systems or organs, as indicated by patient symptoms, AEs, or other findings . 
4. ECG to be completed after the patient has been in the supine position for a minimum of 5 minutes.  ECG to be conducted before vital signs or blood draws if scheduled at the 
same visit.  
5. Height without shoes is measured at the screening visit only.  
6. Laboratory safety tests include panels for haematology, clinical chemistry, and urinalysis. At screening only, patients will also be tested for HCV and HBsAg.  
7. Transaminases (ALT and AST) along with bilirubin will be obtained to monitor liver function.  These assessments may be comple ted by a local laboratory and reported to the 
clinical site, if necessary .   
8. Testosterone and PSA  blood samples are to be  collected between 7 and 10 in the morning.  
9. Completed only in a cohort of up to 8 patients randomized to TAVT -45 at select site(s) only. Patients are to take their TAVT -45 morning dose  in the fasted state (following an 
overnight fas t of at least 8 h) on Days 1 and 9 and will continue to fast  for 2 h after morning dose administration after which a normal meal schedule can be resumed.  The 
morning dose administered on Days 1 and 9 will be reconstituted with water. Allowable windows for PK sample collection are provided in Section 6.6. 
10. All patients will have pre -dose blood samples collected. However, a separate sample on Day 9 is not needed if this Day 9 pre-dose sample is already being collected as part of 
the serial PK sampling cohort.  Reconstitution fluid used for the previous dose (water or specified juice) will be recorded in the eCRF on days of trough sampling.  
11. All AEs /SAEs occurring after the patient has provided informed consent must be reported.  
12. This randomization  step will be the last activity to occur during the Screening window. Sites will contact the IRT system  only after confirming  all eligibility  criteria and 
receiving the screening testosterone value that is needed for stratification . 
 
Confidential  
EudraCT 2020 -005611 -46 Page 43 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
  
6.1 Information to be collected on screen failures  
Patient s may discontinue from the study prior to randomization. These patients  are considered 
screen failures.  If a patient  discontinues before entering the treatment period at baseline, the reason 
for not being randomized will be entered on the  CRF.  
All patient s who have signed informed consent and are randomized into the Treatment Period of 
the study will have all AEs oc curring after informed consent is signed recorded on the Adverse 
Event CRF.   
 
6.2 Subject demographics/other baseline  characteristics  
Patient  demographic , baseline characteristic , and medical history data must be collected on all 
patient s and recorded in the CRF. Also, medical history relevant to prostate cancer (s uch as date 
of diagnosis  and Gleason score ) should also be recorded. Whenever possible, diagnoses and not 
symptoms will be recorded. Investigators will have the discretion to record abnormal test findings 
on the medical history CRF whenever in their judgment. 
 
6.3 Treatment exposure and compliance  
All dates of study treatment dispensing will be recorded on the appropriate CRF. Drugs 
administered prior to start of treatment and other drugs/procedures continuing or started during 
the study treatment period will be entered in the Prior/Concomitant medications  CRF.   
Compliance (adherence) is expected to be 100% . During each Treatment Period, the number of 
granule sachets or tablets dispensed and returned will be counted to determine compliance with dosing regi men for TAVT -45, R -AA and prednisone. Compliance (adherence) will also be 
assessed by  a study monitor using information provided by the authorized site  personnel.  
 
6.4 Contraception   
All sexually active patients must use a condom. Male patients who are sexually active with a 
female partner of child -bearing potential * must use, with their partner, a condom plus an approved 
method of highly effective contraception from the time of informed consent until 3 weeks  after 
the last dose of study medication.   
A highly effective method of contraception is defined as one that has no higher than a 1% failure rate. In this study, the only highly effective methods of contraception are:  
 
 
• Partner’s use of combined (oestrogen and  progestogen- containing) hormonal 
contraception:    
• Oral 
• Intravaginal  
• Transdermal  
• Partner’s use of progestogen- only hormonal contraception associated with inhibition 
of ovulation:    
• Oral   
• Injectable/implantable    
• Intrauterine hormone -releasing system   
• Partner’s use of implantable intrauterine device   
Confidential  
EudraCT 2020 -005611 -46 Page 44 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 • Surgical sterilization (for example, vasectomy or partner’s bilateral tubal occlusion , 
provided that partner is the sole sexual partner of a study patient of child- bearing 
potential and that the vasectomize d partner has received medical assessment of the 
surgical success )  
Alternatively, true abstinence is acceptable when it is in line with the patient ’s preferred and usual 
lifestyle. Periodic abstinence ( eg, calendar, ovulation, symptothermal, post ovulation methods for 
the female partner ) and withdrawal are not acceptable methods of contraception. If a patient  is 
usually not sexually active but becomes active, they, with their partner, they must comply with 
the contraceptive requirements detailed above.  
*For clarification, a women of childbearing potential (WOCBP) is defined as any female who 
has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post menopausal 
(defined as amenorrhea ≥12 consecutive months; or women on hormone replacement therapy with documented serum follicle -stimulating hormone level ≥35 mIU/mL).  
6.4.1  
Exposure to Partners During the Study   
There is a significant risk of drug exposure through the ejaculate (which also applies to vasectomized  males) that might be harmful to the sexual partners (both male and female), 
including pregnant partners of male patients . Therefore, a condom should be used by all male 
subjects from the time of informed consent until three weeks  after the last dose of study 
medication . 
 
6.4.2  Sperm Donation  
Male patients should not donate sperm from the time of informed consent until three weeks after the last dose of study medication.
 
6.5 Efficacy assessments  
6.5.1  Serum testosterone  
Samples for serum testosterone during the Screening period will be taken between 7 am and 10 am .  The result of this serum testosterone will be used to qualify the patient f or participation 
in the trial and to randomize eligible patients  with stratification by testosterone level.   
Samples for serum testosterone assessment point s during the treatment period as  specified in 
Table 1 should be taken between 7 and 10 in the morning and be  analyzed using a validated and  
ultrasensitive testosterone assay  at a central laboratory with a lower limit of quantification 
(LLOQ) of 0 .1 ng/dL .  The serum testosterone obtained pre -dose on Day 1 will be the baseline 
value for any testosterone change from baseline comparisons  during the treatment period.  
6.5.2  
Prostate-specific antigen  
Samples for PSA will be collected as specified in Table 1 should be taken between 7 and 10 in 
the morning and analyzed using a validated and ultrasensitive PSA assay at a central  reference  
laboratory.  
6.5.3  Abiraterone trough concentrations  
Blood s amples for abiraterone trough concentrations will be collected on Days 9, 28, 56 and 84 
(taken before dosing)  for all patients . Study staff will remind patients to withhold their morning 
study medication administration on these visit days.  The reconstitution fluid (water or specified juice) used for administration of the previous dose will be recorded in the eCRF on days of trough 
sampling. 
Abiraterone trough concentrations will be analyzed using a validated bioanalytical method.   
Confidential  
EudraCT 2020 -005611 -46 Page 45 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 6.6 Pharmacokinetics 
For a cohort of up to 8 patients randomized to TAVT -45 granules  and participating in the serial 
PK sampling on Day 1 and Day 9, blood samples (approximately 4 mL)  will be collected at the 
following times:  
• Day 1 : at pre-dose (± 30 min), and 0.25 (± 5 min) , 0.5 (± 5 min) , 0.75 (± 5 min) ,  
1 (± 5 min) , 1.5 (± 10 min) , 2 (± 10 min) , 3 (± 10 min) , 4 (± 30 min) , 8 (± 30 min) ,  
10 (± 30 min ), and 12 (± 30 min ) hours post-dose and before the scheduled evening dose  
• Day 9:  at pre-dose (± 30 min), and 0.25 (±  5 min), 0.5 (± 5 min) , 0.75 (± 5 min) ,  
1 (± 5 min) , 1.5 (± 10 min), 2 (± 10 min) , 3 (± 10 min) , 4 (± 30 min) , 8 (± 30 min) ,  
10 (± 30 min), and 12 (± 30 min)  hours post-dose and before the scheduled evening dose 
Patients will be in the fasted state  (overnight fast of at least 8 h)  at the time of morning TAVT -45 
administration and will remain fasted for 2 hours after morning dose adminis tration after which 
time the normal meal schedule may be resumed. The morning dose of TAVT -45 granules will be 
reconstituted with water on Days 1 and 9.  Abiraterone concentrations in these serial samples will  
be analyzed using a validated bioanalytical method.   
6.7 Safety 
All safety assessments should be done prior to study treatment administration. Appropriate safety 
assessments should be repeated after the dose is administered  as per Table 1. 
Safety assessments will include: 
• Clinical chemistry  and hematology  
• Vital signs  
• Electrocardiograms  
• Physical examination  
• AEs 
6.7.1  Clinical laboratory assessments  
At Screening only, patients will be tested for HCV and HBsAg to determine eligibility.  
At Screening and during the study, l aboratory safety  tests will also be performed according to the 
time schedule presented in Table 1.  The following parameters will be collected: 
• Haematology :  Haemoglobin, Platelet Count, White Blood Cells, including  absolute 
neutrophil count (ANC)  
• Clinical Chemistry : Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase 
(ALP), Aspartate Aminotransferase (AST), Bilirubin (Total), Bilirubin (Direct) (only 
if Total is elevated), Creatine Kinase, Creatinine, Gamma Glutamyl Transferase, Glucose (Fasting), L actate Dehydrogenase , Potassium, Phosphate (Inorganic), Protein 
(Total), Sodium, Urea 
• Urinalysis : Bilirubin, Blood, Glucose, Ketones, Leukocytes, Nitrites, pH, Protein, 
Specific gravity, Urobilinogen 
In cases where laboratory findings are outside the normal range and the investigator believes that the results may be of clinical significance, repeat sampling may be requested as clinically indicated. If the abnormal finding is clinically significant, appropriate actions will be taken e .g., 
Confidential  
EudraCT 2020 -005611 -46 Page 46 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 the patient  may not be ent ered into the study or the patient  may be withdrawn from the study. The 
patient  will be referred to their general practitioner  or other appropriate provider for further care.  
Any clinically significant abnormality, including changes from baseline, must be  reported as an 
AE. 
Additional blood and/or urine samples may be taken for safety tests. Furthermore, additional 
assays outside those specified in the protocol may be performed for safety reasons as requested by the investigator. 
6.7.2  
Vital s igns 
Vital signs  will be performed  according to the time schedule presented in Table 1. Vital sign 
assessments will include blood pressure , heart  rate, respiratory rate  and body temperature ; body 
weight will also be measured according to the time schedule presented in Table 1, with the patient  
lightly clothed and without shoe s. Patient  height (without shoes) will be measured at S creening 
only. 
If a patient  shows an abnormal assessment at any stage, repeat measurements may be made and 
the abnormality followed to resolution if required. Additional measurements may be taken as 
deemed neces sary by the investigator  
Any clinically significant abnormality, including changes from baseline, must be reported as an AE. 
6.7.3  
Electrocardiograms  
Twelve- lead ECGs will be conducted at Screening, after the patient  has been in the supine position 
for a minimum of 5 min. If possible, it is preferred that ECGs be conducted prior to vital sign 
assessments or blood draws  if scheduled for the same visit . 
6.7.4  Physical examination 
The physical examination will include the examination of general appearance, skin, lungs, he art, 
abdomen, lymph nodes, extremities  and vascular  system.  Patient s will have a full physical 
examination at Screening, and then abbreviated exams during each subsequent visit  that will be 
targeted assessment(s) of the body systems or organs, as indicated by patient symptoms, AEs, or 
other findings . 
Information for all physical examinations must be included in the source documentation at the 
study site. Significant findings that are present before si gning the ICF must be included in the 
relevant medical history CRF. Significant findings made after signing the ICF which meet the 
definition of an AE must be recorded in the Adverse Event  CRF.  
7  SAFETY  MONITORING  
7.1 Adverse events  
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign, including clinically significant abnormal laboratory findings, symptom or 
disease) in a clinical investigation patient  after providing informed consent for  participation in 
the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
An adverse reaction is any untoward and unintended responses to study trea tment related to any 
dose administered.  
Confidential  
EudraCT 2020 -005611 -46 Page 47 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 An unexpected adverse reaction is an adverse reaction in which the nature or severity is not 
consistent with the Reference Safety Information (RSI) outlined in the IB (for TAVT -45) or 
SmPC (for R -AA).  
All AEs sponta neously reported by the patient or reported in response to the open- ended and 
non-leading verbal questioning from the study personnel (e.g., “How are you feeling?” “Have 
you had any health problems since the previous visit/you were last asked?”), or reveal ed by 
observation will be collected and recorded in the CRF.  
Abnormal laboratory values or test results constitute AEs only if they are clinically significant, 
which is defined as fulfilling at least one of the following criteria:  
• they induce clinical sig ns or  symptoms, 
• they fulfil any of the criteria for a serious adverse event , 
• they require  therapy  
• they cause a dose reduction, or interruption or discontinuation of a medication 
• they cause study withdrawal  
• they require additional investigation 
Adverse events must be recorded in the Adverse Events CRF, accompanied by the following information:  
• the severity  (intensity)  grades  according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), Version 5.0 or higher  that has 
unique clinical descriptions of severity for each adverse event, but follows the following guidelines:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.  
• Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living ( ADL) (preparing 
meals, shopping for groceries or clothes, using the telephone, managing money, etc).  
• Grade 3: Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; li miting 
self-care ADL (bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden).  
• Grade 4: Life- threatening consequences; urgent intervention indicated.  
• Grade 5 : Death related to AE.  
• its relationship to the study treatment (TAVT -45 or R -AA). See NOTE below 
• Related: There is a reasonable possibility that the event may have been caused 
by the study treatment.  
• Not related: The adverse event can be readily explained by other plausible factors such as medical hist ory; lack of efficacy / worsening of the treated 
condition; concomitant medication, or no obvious temporal relationship exists between the study medication and the adverse event .  
• its duration (start and end dates) or if the event is ongoing an outcome of not recovered/not resolved must be  reported  
• outcome  
Confidential  
EudraCT 2020 -005611 -46 Page 48 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 • whether it constitutes a serious adverse event and which seriousness criteria have been  
met 
• action taken regarding investigational  treatment.  
 
NOTE : Causality (relationship between each AE and study treat ment) must be carefully  
considered to answer a question:  Is there a reasonable possibility that the AE or SAE may have 
been caused by the study treatment? The investigator must endeavor to obtain sufficient  
information to support the causa lity of the AE a nd give their opinion of the causal relationship  
between each AE and study treatment considering the following (list not exhaustive) : time  latency, 
concurrent conditions (including disease under study), concomitant medications, dechallenge 
(even resolves o r improves after interruption of study treatment) or rechallenge (event reappea rs 
or worsens when dosing is resumed) and pharmacological activity of study treatment.  
Once an AE is detected, it must be followed until its resolution, until it is judged to be  permanent,  
or it becomes unlikely that any additional information can be obtained. A ssessment must be made 
at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the  outcome. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a given etiology. In such cases, the diagnosis should be documented as the adverse event. Associated signs or symptoms not generally attributed to a given diagnosis should be recorded separately.  
If deterioration in a laboratory value, vital sign, ECG or other safety assessment is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result or other finding will be considered as additional information. Wherever possible the reporting investigator uses the clinical, rather than the laboratory term (e.g, anaemia versus low haemoglobin value). In the absence of cli nical signs and symptoms, clinically relevant 
deteriorations in non- mandated parameters should be reported as AE(s).  
Deterioration of eg.  laboratory value  or other safety assessment  that is unequivocally due to 
disease progression should not be reported a s an AE.  
To ensure patient  safety, every AE, regardless of causality, occurring after the patient  has provided 
informed consent and until the Follow -up Visit must be captured via the eCRF as soon as possible 
on learning of its occurrence . AE follow up inf ormation will be collected as required until either 
the event is considered as resolved, agreed as not possible to resolve or until the patient is lost to follow up.     
7.2 Serious adverse  events  
7.2.1  Definition of SAE  
An AE or suspected adverse reaction is considered serious (SAE) if, in the view of either the investigator or sponsor, it meets any one of the following criteria:  
• Death.  
• Life-threatening.  Life -threatening means that the patient was at immediate risk of death 
from the reaction as it occurred, i .e., it does not include a reaction which hypothetically 
might have caused death had it occurred in a more severe form.  
• In-patient hospitalization or prolongation of existing hospitalization.  Note: an 
emergency room or urgent care visit without hospital a dmission will not be recorded as 
an SAE under this criterion, nor will hospitalization for a procedure scheduled or 
Confidential  
EudraCT 2020 -005611 -46 Page 49 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 planned before signing of informed consent, or elective treatment of a pre -existing 
condition that did not worsen from baseline. However, unexpected complications 
and/or prolongation of hospitalization that occur during elective surgery should be recorded as AEs and assessed for seriousness. Admission to the hospital for social or situational reasons (i.e., no place to stay, live too far away to come for hospital visits, respite care) will not be considered serious.  
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.  
• Congenital anomaly/birth defect.  
• Important medical event.  An impor tant medical event is an event that may not result 
in death, be life -threatening, or require hospitalization but may be considered an SAE 
when, based upon appropriate medical judgment, it may jeopardize the patient or patient and may require medical or sur gical intervention to prevent one of the outcomes 
listed in the definitions for SAEs.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in -patient hospitalization, or the 
development of drug dependency or drug abuse. All malignant neoplasms will be 
assessed as a medically important event if other seriousness criteria are not met.  
Any suspected transmission via a medicinal product  of an infectious agent is also considered a 
serious adverse reaction. All AEs (serious and non -serious) are captured on the e CRF.  
7.2.2  SAE reporting  
To ensure patient  safety, every SAE, regardless of causality, occurring after the patient  has 
provided informed consent and until the Follow -up Visit must be reported to T avanta or 
designee  within 24 hours of learning of its occurrence  (see Safety contact information below) . 
Any SAEs experienced after this period should only be reported to T avanta  or designee  if the 
investigator suspects a causal relationship to study treatment.  
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new  event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report.  At a minimum, the following information should be provided:  
• Sponsor study number  
• Subject number  
• Valid reporter (reporter and PI signature)  
• Event term (Diagnosis if available, symptoms if not)  
• Suspected study medications (IMPs)  
• Causality assessment  
 
Confidential  
EudraCT 2020 -005611 -46 Page 50 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 Safety Contact Information: 
TMC Pharma Services Ltd  (Pharmacovigilance)  
E-mail: tavanta@tmcpharma.com   
Telephone (24/7) : +44 1252 84 22 55 
Facsimile  USA: +1  617 6636 222  
Fax Europe/ROW : +44 1189 00 78 22 
7.2.3  Expedited Reporting  
The sponsor /designee will report all relevant information about suspected unexpected serious 
adverse reactions (SUSARs) that are fatal or life -threatening as soon as possible to the FDA, 
applicable regulatory authorities in all the concerned countries , and to the Central Ethics 
Committee (s), and in any case no later than seven days after knowledge by the sponsor /designee 
of such a case.    
All other serious cases and any significant new information on an already reported case received 
by the sponsor  meeting  SUSAR  criteria  will be reported to the FDA, applicable regulatory 
authorities concerned and to the Central Ethics Committee (s) concerned as soon as possible but 
within a maximum of 15 days of first knowledge by the sponsor/designee.  
The sponsor/designee will also report any additional expedited safety reports required in 
accordance with the timelines outlined in country- specific legislation.  
The sponsor/designee will also inform all investigators  as required per local regulation.  
The requirements above refer to the requirements relating to the investigational medicinal product. Expedited reporting of suspected unexpected serious adverse reactions related to R- AA is also 
required in line with the requirements above. 
Expedited reporting of suspected unexpected serious adverse reactions related to prednisone (and 
any other non-investigational medical products) is not required.  
7.3 Adverse Events of Special Interest 
The following will be considered adverse events of special interest (AESI) : 
• Hepatotoxicity  
• Symptomatic adrenocortical insufficiency  
• Hypertension, hypokalemia and/or edema appearing together, suggestive of mineralocorticoid excess  
• Hypoglycemia 
Regardless of seriousness, the Investigator shall provide detailed initial information and follow-up using the same reporting process as for SAE reporting (see details in Section 7.2.2) within 24 hours of awareness.  
7.4 Overdose and dosing errors 
Special situations may require expedited reporting and/or safety evaluation. This may include: 
• Overdose of a study treatment 
• Suspected abuse/misuse of study treatment 
• Inadvertent or accidental exposure to study treatment 
Confidential  
EudraCT 2020 -005611 -46 Page 51 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 • Medication error involving study tr eatment  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient  or 
consumer (EMA  definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the protocol. Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, which is accompanied by harmful physical or psychological ef fects.  
A study treatment overdose is the accidental or intentional use of study treatment in an amount 
higher than the dose being studied. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded in 
the relevant sections of clinical database i rrespective of whether or not associated with an 
AE/SAE .  Should a treatment error be associated with an SAE , then t his would need to be 
reported to safety within 24 hours of awareness as per the guidance on SAE reporting in 
Section  7.2.2. 
 
7.5 Pregnancy reporting 
To e nsure patient  safety, each pregnancy of a female partner of a male patient on study 
treatment, must be reported to T avanta or designee within 24 hours of learning of its occurrence. 
Following consent from the female partner (non -trial participant), t he pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.  
Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by the investigator to T avanta  or designee  using the same safety contact information as used for SAE 
reporting (see details in  Section 7.2.2) . Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment.  
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported on a SAE form.  
 
8 DATA REVIEW AND DATABASE  MANAGEMENT  
8.1 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Tavanta 
representative or designee will review the protocol and data capture requirements (i.e. CRFs) with 
the investigators and their staff. During the study, Tavanta employs several methods of ensuring 
protocol and Good Clinical Practice (GCP) compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of patient  records, the accuracy of 
data capture / data entry, the adherence to the protocol and to GCP, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Continuous monitoring of each site’s data may be performed by a CRO .  
The investigator must maintain source documents for each patient  in the study, consisting of case 
and visit notes (hospital or clinic medical records) containing demographic and medical information, and the results of any other tests or assessments. All information on CRFs must be 
Confidential  
EudraCT 2020 -005611 -46 Page 52 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 traceable to these source documents in  the patient 's file. The investigator must also keep the 
original informed consent form signed by the patient  (a signed copy is given to the  patient ). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consisten cy with the data capture and/or CRF entries. T avanta monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary va riables. Additional checks 
of the consistency of the source data with the CRFs are performed according to the study- specific 
monitoring plan. No information in source documents about the identity of the patient s will be  
disclosed. 
8.2 Data collection  
The Inves tigator must certify that the data entered into the CRF  are complete and accurate. After  
database lock, the investigator will receive copies of the patient  data for archiving at the 
investigational site.  
8.3 Database management and quality  control 
CRO/ Tavanta staff will review the data entered into the CRFs by investigational staff for 
completeness and accuracy and instruct the site personnel to make any required corrections or additions. Queries can be asked to the investigational site. Designated investigator  site staff is 
required to respond to the query and confirm or correct the data.  All queries and responses are subject to an audit trail.  
Concomitant medications entered into  the database will be coded using the World H ealth 
Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Concomitant procedures, non- drug therapies and AEs will be coded using 
the Medical Dictionar y for Regulatory Activities (MedDRA) terminology. 
Randomization codes and data about all study drug(s) dispensed to the patient  and all dosage 
changes will be tracked . Each occurrence of a code break w ill be reported to the clinical team and 
monitor. The c ode break functionality will remain available until study shut down or upon request 
of Tavanta . 
The occurrence of relevant protocol deviations will be determined. After these actions have been completed and the database has been declared to be complete and  accurate, it will be locked, and 
the treatment codes will be made available for data analysis.  
8.4 Data Monitoring Committee  
An independent data monitoring committee (DMC) will be established to review the safety data collected during the conduct of the study and monitor the progress of the study.  
Details of the composition, roles, and responsibilities, and processes of the DMC will be  
documented in a separate DMC C harter. The DMC will review safety data at specified intervals 
and can make recommendation s to the Sponsor to stop or amend the study on the basis of safety 
findings. The frequency of these reviews , as well as the data to be reviewed , will be agreed with 
the DMC and outlined in the Charter, with DMC review meetings being held in a blinded manne r 
to the Sponsor . Outcomes of the DMC review meetings will be shared by T avanta or designee 
with the Investigators.  
Confidential  
EudraCT 2020 -005611 -46 Page 53 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 9 DATA ANALYSIS  
9.1 Study design  
This is a Phase 3 randomized, open- label study to evaluate the pharmacodynamic effect of 
TAVT -45 compared to Zytiga (reference abiraterone acetate formulation, hereafter referred to as 
R-AA) in patients with mCSPC (distant metastases) an d mCRPC. Randomizat ion will be stratified 
by prostate cancer population (CSPC vs CRPC) and baseline testosterone (<10 vs ≥ 10 ng/ dL). 
Patients will be treated for 84 days and randomized into one of two groups in a 1:1 ratio: 
• TAVT -45:  Administered twice daily as 1 x sachet containing TAVT -45 (250 mg abiraterone 
acetate) + Prednisone (5 mg once or twice daily, depending on prostate cancer population)  
• R-AA once daily:  Ad ministered once daily as (2 x 500 mg Zytiga tablets) + Prednisone 
(5 mg once or twice daily, depending on prostate cancer population)  
It is planned to enroll 10 8 patients in this study (n= 54 patients per prostate cancer population), 
randomized in a 1:1 ratio receiving either TAVT -45 (n=27 mCRPC and n= 27 mCSPC patients) 
or R-AA (n= 27 mCRPC and n= 27 m CSPC patients).  
9.2 Efficacy endpoints  
The primary efficacy endpoint is the comparison of the average of serum testosterone levels on 
days 9 and 10 between groups ( TAVT -45 vs R -AA).  
The key secondary efficacy endpoint  is the PSA-50 response, defined as a decrease of ≥  50% in 
PSA levels from baseline  at any time over the 84 -day post -treatment period . 
Other secondary efficacy endpoints are as follows:  
• Serum testosterone levels at Day s 28, 56 and 84  
• PSA-50 response at Days 28, 56 and 84 
• PSA levels at Day s 28, 56 and 84 
• Trough concentrations of abiraterone at Days 9, 28, 56 and 84 
9.3 Safety endpoints  
The following safety endpoints will also be assessed:  
• Incidence of treatment -emergent adverse events (TEAEs)  
• Physical examination findings  
• Clinical laboratory asse ssments , including potentially c linically significant changes  
• Vital signs measurements, including potentially clinically significant changes  
Safety variables will be summarized descriptively. The number and percentage of patient s with 
abnormal or potentially clinically significant clinical laboratory values  and vital sign 
measurements will be summarized by treatment.  
9.4 Pharmacokinetic endpoints  
For a cohort of up to 8 patients randomized to TAVT -45 and participating in the serial PK 
sampling on Day 1 and Day 9, the following PK parameters will be determined:  
• Area under the concentration -time curve from time zero to 12 hours post dose  
(AUC 0-12)  
• Maximum measured plasma concentration (C max)  
• Minimum measured plasma concentration (C min)  
Confidential  
EudraCT 2020 -005611 -46 Page 54 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 • Time to maximum measured concentration (t max)  
• Accumulation ratio (Rac)  
• Effective half -life (t½)  
9.5 Other endpoint s 
Other exploratory endpoints may be described within the study SAP .  
9.6 Sample size  
In this study, the effects of TAVT -45 250 mg BID on serum testosterone will be compared to 
R-AA (given at 1000 mg QD) based on the equivalence approach of determining the 90% 
confidence interval (CI) of the test -to-reference geometric mean ratio  within the 80 to 125% 
equivalence limit  [ 1,2].  
Under the assumptions of a coefficient of variation of 25%, a lower and upper limit of 80% to 
125%, and an expected test -to-reference ratio of 1.05, 108 patients in total ( 54 patients in TAVT -
45 and 54 patients in R -AA) will provide approximately  80% power (two one -sided t -tests at 0.05 
level) to conclude therapeutic equivalence of TAV T-45 to R -AA. 
Among the total 108 patients planned for this study, a t least  54 mCRPC patients  must be enrolled 
(n=27 in each treatment arm ), which will provide at least 80% power  for mCRPC patients . This 
sample size for each cancer population is also consistent with a similarly designed trial evaluating 
the therapeutic equivalence of R -AA and an abiraterone acetate fine particle formulation  [15].  
To ensure  an ad equate number of patients are enrolled  given the above sample size considerations , 
additional patients may be randomized to ensure that a total of 108 patients are treated up through 
Day 9 for collection of the primary efficacy endpoint data. 
9.7 Data analysis   
This section presents a summary of the planned statistical analyses. Before database lock, a final Statistical Analysis Plan (SAP) will be prepared that will con tain full details of all planned 
analyses.  Any deviations from the planned analyses will be described and justified in the clinical study report . 
9.7.1  
General analyses  
Statistical analysis will be performed on the following populations:  
• mCRPC Intent -to-treat population  (CR-ITT) : All randomized patients  who have mCRPC  
• Intent -to-treat population  (ITT) : All randomized patients  inclusive of both mCRPC and 
mCSPC  
• Safety population:  All randomized patient s who receive at least one dose of study 
medication, including those who do not complete the study.  
• Per-protocol population: All randomized patient s who do not have a major protocol 
deviation that could potentially impact efficacy . 
 
All original and derived parameters as well as demographic data will be listed and described using summary statistics. Frequency counts (number of patient s and percentages) will be made for each 
qualitative variable. Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be calculated for each quantitative variable (unless otherwise stated) and will be presented by treatment (if applicable).  
Confidential  
EudraCT 2020 -005611 -46 Page 55 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 If not otherwise specified, ‘baseline’ refers to the last non- missing observation before study 
medication administration. All statistical tests will be two -sided and performed at the 5% level of 
significance, unless otherwise stated.  
For c hanges from baseline, only changes subsequent to the defined baseline will be shown in the 
listings and tabulations; in the listings any repeat/unscheduled measurements will be included in 
chronological order with the scheduled measurements, no unscheduled and/or repeated 
measurements (unless used as the baseline measurement) will be included in the tables . 
Handling of Missing and Incomplete Data  
If any baseline value is missing, the screening value will be used.  Post baseline missing values will be kept a s missing.  For efficacy data analyses, different missing data imputation methods 
may be explored to test the robustness of the primary efficacy analysis method and will be defined 
within the SAP . 
9.7.2  
Efficacy data  analys es 
The primary endpoint, the average serum testosterone  levels on days 9 and 10, will be analyzed 
by an analysis of variance (ANOVA) model  with treatment as a factor . The test -to-reference 
geometric mean ratio effect and its 90% confidence interval (CI)  of TAVT -45 to R-AA will be 
compared to  80% to 125%  limit.  
The primary analysis will be performed based on the CR- ITT and repeated on the  ITT and per-
protocol populations .  
Differen t missing data imputation approaches will be used as sensitivity analyses based on the 
intent -to-treat population  and will be defined within the SAP .  
PSA-50 response at any time over the 84- day post -treatment period will be analyzed by a logistic 
model with treatment as a factor. Odds ratio, 95 % CI using modified Wilson score method of 
TAVT -45 to R -AA will be presented.  
Serum testoster one levels at Days 28, 56 and 84 will be analyzed as the same manner as the 
primary endpoint.  
PSA-50 response at Days 28, 56 and 84 will be analyzed by a logistic model with treatment as a 
factor. Odds ratio, 95% CI and p -value will be presented.  
Trough c oncentrations of abiraterone at Days 9, 28, 56 and 84 will be summarized descriptively. 
The number of patients with trough concentrations abiraterone above and below 8.4 ng/mL at Days 9, 28, and 56 will also be summarized.  
Regarding subgroup analysis, both the primary and key secondary efficacy endpoints will also be 
repeated on the CSPC patients.  
Confidential  
EudraCT 2020 -005611 -46 Page 56 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 9.7.3  Multiplicity and testing s trategy  
In order to  control the family -wise type I error, a sequential testing procedure will be 
implemented. The primary endpoint, the average of serum testosterone levels on days 9 and 10, 
will be tested using two one -sided t -tests at 0.05 alpha [ 1,2].  
If the equivalence of the average of serum testosterone levels on days 9 and 10 is achieved, th en 
the key secondary endpoint  (PSA-50 response, defined as a decrease of ≥50% in PSA levels from 
baseline at any time over the 84- day post -treatment period ) will be tested at 0.05 alpha level.  
The primary and key secondary efficacy endpoints will be teste d for mCRPC population using 
CR-ITT population first. If rejected, the same primary and key secondary efficacy endpoints will 
also be tested for the overall population using the ITT population. 
9.7.4  Safety d ata analyses 
Treatment -emergent AEs (TEAEs) are defined as  adverse events that started after the first dose 
of study drug ( reference or test)  or events present prior to the first dose of study treatment but 
increased in severity based on preferred term) will be summari zed.  Non-treatment- emergent AEs 
will be presented  in a listing but not summarized  by treatment group.  
TEAEs will be summarized by treatment group;  the number and percentage of patient s having 
any AE, having an AE in each primary system organ class and having each individual AE  will be 
presented .  Summaries will also be presented for AEs by severity and for study treatment related 
AEs.  If a patient  reported more than one AE with the same preferred term, the AE with the 
greatest severity will be presented. If a patient  reported more than one AE within the same primary 
system organ class, the patient  will be counted only once with the greatest severity at the system 
organ class level, where applicable. SAEs will also be summarized.  Separate summaries will be  
provided for death, SAE, other TEAEs leading to study treatment interruption or study treatment 
discontinuation. 
The number and percentage of patient s with abnormal or potentially clinically significant clinical 
laboratory values and vital sign measurements will be summarized by treatment.  These thresholds 
will be pre -defined within the SAP. 
9.7.5  Pharmacokinetic data analyses  
Plasma samples will be analyzed using a validated assay; the samples from all evaluable patient s 
will be analyzed.  PK parameters for abi raterone will be calculated using a non- compartmental 
analysis . 
Patients  who are dosed and who have sufficient concentration- time data to report at least one PK 
parameter will be included in the PK analysis.  PK calculations will be performed using Phoenix™ 
WinNonlin® (Version 8.0 or higher, Pharsight Corporation) and/or SAS ® (Version 9.4 or higher, 
SAS Institute Inc.). Additional details regarding the PK analysis will be included within the SAP.  
Abiraterone concentration -time data and PK parameters will be summarized by treatment group 
using descriptive statistics  (n, mean, SD, min, median, max, and CV%).  Procedures for 
accounting for missing, unused, or spurious data, specific to the PK analyses, will be outlined 
separately in the SAP.  
9.7.6  Other analyses  
Additional analyses, including other subgroup analyses  and other exploratory analyses , will be 
described in the SAP . 
Confidential  
EudraCT 2020 -005611 -46 Page 57 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 10 ETHICAL CONSIDERATIONS  
10.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC), and with the ethical principles laid down in the Declaration of Helsinki.  
10.2 Informed consent procedures  
Eligible patient s may only be included in the study after providing the approved Informed 
Consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable 
representative(s) of the patient . In c ases where the patient ’s representative gives consent, the 
patient  should be informed about the study to the extent possible given his/her understanding. If 
the patient  is capable of doing so, he/she must indicate assent by personally signing and dating the  
Informed Consent document or a separate assent form. Informed C onsent must be obtained before 
conducting any study- specific procedures (e.g. all of the procedures described in the protoc ol). 
The process of obtaining informed consent must be documented in the patient  source  documents. 
Tavanta will provide to investigators in a separate document a proposed Informed Consent form 
that complies with the ICH GCP guideline and regulatory require ments and is considered 
appropriate for this study. 
10.3 Responsibilities of the investigator  
Prior to study start, the investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study in accordance with these documents and all of the instructions and 
procedures found in this protocol . 
If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform T avanta immediately that this request has been  made.  
The investigator must perm it study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents . 
10.4 Publication of study protocol and  results  
Tavanta assures that the key design elements of this protocol will be poste d in a publicly accessible 
database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of cl inical trial results.  
11 PROTOCOL  ADHERENCE  
This protocol defines the study objectives, the study procedures  and the data to be collected on 
study participants. Additional assessments required to ensure safety of patient s should be 
administered as deemed necessary on a case by case basis. Under no circumstances is an investigator allowed to collect additional da ta or conduct any additional procedures for any 
research related purpose involving any investigational  drugs.  
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by T avanta, it 
cannot be implemented. All significant protocol deviations will be recorded and reported in the clinical study report . 
Confidential  
EudraCT 2020 -005611 -46 Page 58 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 12 PROTOCOL AMENDMENTS 
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by T avanta, Health Authorities prior to implementation. Only amendments that 
are intended to eliminate an apparent immediate h azard to patient s/subjects may be implemented 
immediately provided the H ealth Authorities are subsequently notified by protocol amendment. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any patient  included in this study, 
even if this action represents a deviation from the protocol. 
  
Confidential  
EudraCT 2020 -005611 -46 Page 59 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 13 REFERENCES 
References are available upon request.  
 
1. U.S. Department of Health and Human Services Food and Drug Admini stration/Center for 
Drug Evaluation and Research. (2001). Guidance for Industry: Statistical approaches to 
establishing bioequivalence. 
2. Schurimann DJ. A comparison of the two one -sided tests procedure and the power approach 
for assessing the equivalence of  average bioav ailiability.  J Pharmokin Biopharm. 1987 
15:657-80. 
3. Zytiga Prescribing Information , available at:  
http://www.janssenlabels.co m/package-insert/product-monograph/prescribing-
information/ZYTIGA -pi.pdf   
4. Zytiga SPC/IFU [Internet]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002321/WC500112858.pdf   
5. Kenny C, Regan J, Balding L, et al. Dysphagia prevalence and predictors in cancers outside the head, neck, and upper gastrointestinal tract. J Pain Symptom Manage. 2019;58(6):949-958.e2.  
6. Wakabayashi H, Takahashi R, Watanabe N, et al. Prevalence of sarcopenia and its association  with dysphagia in cancer patients who require rehabilitation. J Rehabil Med.  
2017;49(8):682-685. 
7. Fields J, Go JT, Schulze KS. Pill properties that cause dysphagia and treatment failure. Curr Ther Res Clin Exp. 2015;77:79-82. 6 
8. Investigator’s Brochure for  TAVT -45, a novel abiraterone acetate formulation for oral 
suspension. Tavanta Therapeutics , Inc., Version 5.0.  
9. de Bono JS, Logothetis CJ, Molina A, Fizazi  K, North S, Chu L, et al. Abiraterone and 
increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. 
10. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer w ithout previous chemotherapy. N Engl J Med. 2013 Jan 
10;368(2):138-48. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.  
11. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez -Antolin A, Alekseev BY, et al. 
Abiraterone plus Prednisone in Metastatic, Castration -Sensitive Prostate Cancer.N Engl J 
Med. 2017 Jul 27;377(4):352-360 
12. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017 Jul 27;377(4):338-351. 
13. Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, et al. Relation between plasma trough concentration of abiraterone and prostate -specific antigen response in metastatic 
castration -resistant prostate cancer patients. Eur  J Cancer. 2017 Feb;72:54-61 
14. Clinical pharmacology and biopharmaceutics review(s): application number: 202379Orig1s000. Zytiga. Center for Drug Evaluation and Research, 2011.  (
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.
pdf.) 
Confidential  
EudraCT 2020 -005611 -46 Page 60 
TAVT45C02  
 
 Tavanta Therapeutics , Inc.  
Protocol Version 3.0   
 15. Stein CA, Levin R, Given R, Higano CS, Nemeth P, Bosch B, et al. Randomized phase 2 
therapeutic equivalence study of abiraterone acetate fine par ticle formulation vs. originator 
abiraterone acetate in patients with metastatic castration -resistant prostate cancer: The 
STAAR study. Urol Oncol. 2018 Feb;36(2):81.e9-81.e16 
16. Gomella LG. Effective testosterone suppression for prostate cancer: Is there a b est castration 
therapy. Reviews in Uriology. 2009 Vol 11 (2):52-50.  
17. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, et al. High -Dose Abiraterone Acetate in Men with Castration Resistant Prostate Cancer. 
Clin Genito urin Cancer. 2017 Dec;15(6):733-741 
18. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, et al. Post -therapy serum 
prostate- specific antigen level and survival in patients with androgen- independent prostate 
cancer. J Natl Cancer Inst. 1999 Feb 3;91(3):244-51. 
19. Soluplus Mater ial Safety Data Sheet BASF Safety data sheet according to Regulation (EC) 
No. 1907/2006 Date / Revised: 06.11.2009 Version: 1.3 Product: Soluplus. 
20. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Published: November 27, 2017; Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Qui
ck_Reference_8.5x11.pdf   
21. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Food & Drug Administration. 3 October 2020. Available at: 
https://www.fda.gov/drugs/drug- interactions -labeling/drug-development-and-drug-
interactions -table -substrates-inhibitors- and-inducers#table2-3  
 
 